{"content":"<li class=\"n-box-item date-title\" data-end=\"1552021199\" data-start=\"1551934800\" data-txt=\"Monday, December 23, 2019\">Thursday, March  7, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3441018\" data-ts=\"1552015678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARDX\" target=\"_blank\">ARDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3441018-ardelyx-up-8-after-hours-on-positive-tenapanor-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ardelyx up 8% after hours on positive tenapanor data</a></h4><ul><li>Ardelyx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a>) is up <font color=\"green\">8%</font> after hours in response to a successful <a href=\"https://clinicaltrials.gov/ct2/show/NCT02675998?lead=ardelyx&amp;phase=2&amp;rank=4\" target=\"_blank\">Phase 3 clinical trial</a> evaluating lead drug tenapanor alone for the treatment of hyperphosphatemia (elevated phosphate in the blood) in patients with end-stage renal disease who are on dialysis. The results were just published in the <em>Journal of the American Society of Nephrology</em>.</li><li>The study met the <a href=\"https://seekingalpha.com/pr/17437855-ardelyx-announces-peer-reviewed-publication-positive-phase-3-results-tenapanor-treatment\" target=\"_blank\">primary endpoint</a> demonstrating a statistically significant change in serum phosphorus from baseline in the treatment group compared to placebo after eight weeks of therapy.</li><li>Topline results from a second Phase 3, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03427125?lead=ardelyx&amp;phase=2&amp;rank=1\" target=\"_blank\">PHREEDOM</a>, evaluating tenapanor alone should be available in Q4.</li><li>Preliminary data from a third Phase 3, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03824587?lead=ardelyx&amp;phase=2&amp;rank=6\" target=\"_blank\">AMPLIFY</a>, evaluating tenapanor as adjunctive therapy to phosphate binders, should be available in H2.</li><li>Tenapanor reduces serum phosphate by inhibiting a protein called sodium/hydrogen exchanger 3 (NHE3) that plays a key role in phosphate absorption in the gut via a pathway called passive paracellular flux which occurs between cells. Inhibiting NHE3 decreases the permeability to phosphate which reduces absorption. The mechanism of action appears to be specific to phosphate with no effect on other ions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3441018\" data-linked=\"Ardelyx up 8% after hours on positive tenapanor data\" data-tweet=\"$ARDX - Ardelyx up 8% after hours on positive tenapanor data https://seekingalpha.com/news/3441018-ardelyx-up-8-after-hours-on-positive-tenapanor-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3441018-ardelyx-up-8-after-hours-on-positive-tenapanor-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3441015\" data-ts=\"1552012977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGR\" target=\"_blank\">AVGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3441015-avinger-files-for-50m-mixed-shelf-offering-shares-down-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avinger files for $50M mixed shelf offering; shares down 2% after hours</a></h4><ul><li>Avinger (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGR' title='Avinger'>AVGR</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1506928/000143774919004329/avgr20190301_s3.htm\" target=\"_blank\">prospectus </a>for a $50M mixed shelf offering.</li><li>Shares are down <font color=\"red\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3441015\" data-linked=\"Avinger files for $50M mixed shelf offering; shares down 2% after hours\" data-tweet=\"$AVGR - Avinger files for $50M mixed shelf offering; shares down 2% after hours https://seekingalpha.com/news/3441015-avinger-files-for-50m-mixed-shelf-offering-shares-down-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3441015-avinger-files-for-50m-mixed-shelf-offering-shares-down-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3441005\" data-ts=\"1552000196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMP\" target=\"_blank\">IMMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3441005-immutepplus-11_4-after-positive-preclinical-data-for-imp761\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immutep +11.4% after positive preclinical data for IMP761</a></h4><ul>   <li>Immutep (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMP' title='Immutep Limited ADR'>IMMP</a>) is back among after-hours movers, <font color=\"green\">up 11.4%</font> postmarket after reporting <a href=\"https://seekingalpha.com/pr/17437808-immutep-presents-positive-imp761-preclinical-results-14th-congress-european-crohn-s-colitis\" target=\"_blank\">positive preclinical data</a> for an antibody developed to treat autoimmune diseases.</li>    <li>The company presented results from its study of IMP761, a novel LAG-3 agonist antibody, at the 14th Congress of European Crohn's and Colitis Organisation Conference in Denmark today.</li>    <li>The new study showed IMP761 decreases inflammatory T cell infiltration induced by intradermal injection of an antigen.</li>    <li>IMP761 will advance into clinical development based on the results.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440340-immutep-4-percent-lead-candidate-data\" target=\"_blank\">Immutep down 4% on lead candidate data</a> (Mar. 06 2019)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440100-immutep-plus-11-percent-new-data-tacti-mel-trial\" target=\"_blank\">Immutep +11% after new data from TACTI-mel trial</a> (Mar. 05 2019)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3441005\" data-linked=\"Immutep +11.4% after positive preclinical data for IMP761\" data-tweet=\"$IMMP - Immutep +11.4% after positive preclinical data for IMP761 https://seekingalpha.com/news/3441005-immutepplus-11_4-after-positive-preclinical-data-for-imp761?source=tweet\" data-url=\"https://seekingalpha.com/news/3441005-immutepplus-11_4-after-positive-preclinical-data-for-imp761\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3441001\" data-ts=\"1551999121\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCA\" target=\"_blank\">MDCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3441001-wsj-ad-veteran-penn-in-talks-to-become-ceo-take-stake-mdc-partners\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Ad veteran Penn in talks to become CEO, take stake at MDC Partners</a></h4><ul>   <li>Former Clinton adviser and Madison Ave. veteran Mark Penn is in talks to <a href=\"https://www.wsj.com/articles/madison-avenue-veteran-mark-penn-is-in-talks-to-be-ceo-of-mdc-partners-11551993400?mod=hp_major_pos14\" target=\"_blank\">take over as chief executive</a> at ad-agency firm MDC Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCA' title='MDC Partners Inc.'>MDCA</a>), <i>The Wall Street Journal</i> reports. <a href='https://seekingalpha.com/symbol/MDCA' title='MDC Partners Inc.'>MDCA</a> is <font color=\"green\">up 15.5%</font> after hours.</li>    <li>That is being discussed as part of a deal that would give his investment group a minority stake in the company, according to the report. MDC has been looking for a buyer and a CEO since the fall.</li>    <li>Penn had tried to buy all of MDC before, but the effort didn't go through. If a deal does occur this time, MDC and Penn's Stagwell Group would remain separate entities.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3441001\" data-linked=\"WSJ: Ad veteran Penn in talks to become CEO, take stake at MDC Partners\" data-tweet=\"$MDCA - WSJ: Ad veteran Penn in talks to become CEO, take stake at MDC Partners https://seekingalpha.com/news/3441001-wsj-ad-veteran-penn-in-talks-to-become-ceo-take-stake-mdc-partners?source=tweet\" data-url=\"https://seekingalpha.com/news/3441001-wsj-ad-veteran-penn-in-talks-to-become-ceo-take-stake-mdc-partners\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3441000\" data-ts=\"1551998813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3441000-insy-fizz-immp-and-ardx-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">INSY, FIZZ, IMMP and ARDX among notable after hour movers</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/IMMP' title='Immutep Limited ADR'>IMMP</a> <font color=\"green\">+11.3%</font>. <a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color=\"green\">+10.5%</font>. <a href='https://seekingalpha.com/symbol/SOI' title='Solaris Oilfield Infrastructure'>SOI</a> <font color=\"green\">+8.5%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color=\"green\">+8.4%</font>. <a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software'>UPLD</a> <font color=\"green\">+7.7%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/EB' title='Eventbrite'>EB</a> <font color=\"red\">-24.1%</font>. <a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color=\"red\">-15.6%</font>. <a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color=\"red\">-15.1%</font>. <a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems'>TTOO</a> <font color=\"red\">-14.3%</font>. <a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a> <font color=\"red\">-8.3%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3441000\" data-linked=\"INSY, FIZZ, IMMP and ARDX among notable after hour movers\" data-tweet=\"$IMMP $ARDX $SOI - INSY, FIZZ, IMMP and ARDX among notable after hour movers https://seekingalpha.com/news/3441000-insy-fizz-immp-and-ardx-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3441000-insy-fizz-immp-and-ardx-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440998\" data-ts=\"1551998442\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CWH\" target=\"_blank\">CWH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440998-camping-worldminus-7-on-weak-adjusted-eps\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Camping World -7% on weak adjusted EPS</a></h4><ul><li>Camping World (NYSE:<a href='https://seekingalpha.com/symbol/CWH' title='Camping World Holdings'>CWH</a>) <font color=\"red\">drops 6.8%</font> after Q4 results beat on revenue but included weak EPS of -$0.26, which was $0.44 below consensus.</li><li><a href=\"https://seekingalpha.com/pr/17437747-camping-world-holdings-inc-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Press release.</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3440920-camping-world-eps-0_83\" target=\"_blank\">Camping World EPS of -$0.83</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440998\" data-linked=\"Camping World -7% on weak adjusted EPS\" data-tweet=\"$CWH - Camping World -7% on weak adjusted EPS https://seekingalpha.com/news/3440998-camping-worldminus-7-on-weak-adjusted-eps?source=tweet\" data-url=\"https://seekingalpha.com/news/3440998-camping-worldminus-7-on-weak-adjusted-eps\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440997\" data-ts=\"1551998065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AOBC\" target=\"_blank\">AOBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440997-american-outdoorsminus-4_8-on-firearm-weakness-downside-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Outdoors -4.8% on firearm weakness, downside guide</a></h4><ul><li>American Outdoors (NASDAQ:<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a>) shares <font color=\"red\">drop 4.8%</font> after Q4 beats that included \"ongoing weakness in the firearms market.\"</li><li>To address the problem, AOBC is combining the Electo-Optics division, which contains firearms, with the Outdoor Products &amp; Accessories division.</li><li>Downside FY20 guidance has revenue from $625M to $635M (consensus: $653.77M) and EPS from $0.69 to $0.73 (consensus: $0.85).</li><li><a href=\"https://seekingalpha.com/pr/17437724-american-outdoor-brands-corporation-reports-third-quarter-fiscal-2019-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440894-american-outdoor-brands-beats-0_04-beats-revenue\" target=\"_blank\">American Outdoor Brands beats by $0.04, beats on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440997\" data-linked=\"American Outdoors -4.8% on firearm weakness, downside guide\" data-tweet=\"$AOBC - American Outdoors -4.8% on firearm weakness, downside guide https://seekingalpha.com/news/3440997-american-outdoorsminus-4_8-on-firearm-weakness-downside-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3440997-american-outdoorsminus-4_8-on-firearm-weakness-downside-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440996\" data-ts=\"1551997847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440996-national-beverageminus-15_6-after-missing-lowest-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Beverage -15.6% after missing lowest estimates</a></h4><ul>   <li>National Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a>) has <font color=\"red\">slid 15.6%</font> after its EPS and revenues missed even low-side estimates amid margin pressure spurred by volume declines.</li>    <li>Revenues dropped 3% to $220.9M, and net income fell 40%, to $24.8M in fiscal Q3.</li>    <li>EPS came in at $0.53 vs. estimates for $0.76.</li>    <li>\u201cWe are truly sorry for these results stated above,\" says CEO Nick Caporella in a statement light on financial details, blaming the outcome on \"injustice\" before appealing again to \"patriotism\" of the company's brand.</li>    <li>Comparisons were further skewed by the adoption of the new tax act for last year's Q3, he notes, which included credits and rate reduction adjustments aggregating $11.3M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440965-national-beverage-misses-0_25-misses-revenue\" target=\"_blank\">National Beverage misses by $0.25, misses on revenue</a> (Mar. 07 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17437840-just-love-lacroix-consumers-chant\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3440996\" data-linked=\"National Beverage -15.6% after missing lowest estimates\" data-tweet=\"$FIZZ - National Beverage -15.6% after missing lowest estimates https://seekingalpha.com/news/3440996-national-beverageminus-15_6-after-missing-lowest-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3440996-national-beverageminus-15_6-after-missing-lowest-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440992\" data-ts=\"1551997462\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BJ\" target=\"_blank\">BJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440992-bjsminus-1_5-on-follow-on-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BJ&#39;s -1.5% on follow-on offering</a></h4><ul><li>BJ's Wholesale Club (NYSE:<a href='https://seekingalpha.com/symbol/BJ' title='BJ&#39;s Wholesale Club, Inc.'>BJ</a>) <a href=\"https://seekingalpha.com/pr/17437850-bj-s-wholesale-club-holdings-inc-launches-follow-offering-selling-stockholders\" target=\"_blank\">commences</a> an underwritten public offering of 17M shares by certain selling shareholders.</li><li>The sellers will grant the underwriters a 30-day option to purchase up to an additional 2.55M shares.</li><li>BJ's won't receive any proceeds from the sale but will bear the costs other than underwriting discounts and commissions.</li><li>BJ shares are <font color=\"red\">down 1.5%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440992\" data-linked=\"BJ&#39;s -1.5% on follow-on offering\" data-tweet=\"$BJ - BJ&#39;s -1.5% on follow-on offering https://seekingalpha.com/news/3440992-bjsminus-1_5-on-follow-on-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3440992-bjsminus-1_5-on-follow-on-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440988\" data-ts=\"1551997067\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EB\" target=\"_blank\">EB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440988-eventbriteminus-23-on-wider-expected-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eventbrite -23% on wider than expected loss</a></h4><ul><li>Eventbrite (NYSE:<a href='https://seekingalpha.com/symbol/EB' title='Eventbrite'>EB</a>) <font color=\"red\">plummets 23%</font> after a Q4 EPS miss and downside Q1 revenue guidance of $80M to $84M (consensus: $91.4M).</li><li><a href=\"https://seekingalpha.com/pr/17437744-eventbrite-reports-fourth-quarter-fiscal-year-2018-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440910-eventbrite-misses-0_04-beats-revenue\" target=\"_blank\">Eventbrite misses by $0.04, beats on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440988\" data-linked=\"Eventbrite -23% on wider than expected loss\" data-tweet=\"$EB - Eventbrite -23% on wider than expected loss https://seekingalpha.com/news/3440988-eventbriteminus-23-on-wider-expected-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3440988-eventbriteminus-23-on-wider-expected-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440982\" data-ts=\"1551996643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRVN\" target=\"_blank\">TRVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440982-trevenaminus-13-after-fda-rescinds-breakthrough-designation-for-pain-drug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trevena -13% after FDA rescinds breakthrough designation for pain drug</a></h4><ul><li>Trevena (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>) <font color=\"red\">-12.7%</font> after-hours on disclosing that the <a href=\"https://www.sec.gov/Archives/edgar/data/1429560/000110465919013379/a19-6098_18k.htm\" target=\"_blank\">FDA rescinded its breakthrough designation</a> on the oliceridine pain management drug after data was not sufficient to support the designation.</li><li>The designation was granted in 2016 based on preliminary evidence from Phase 2 clinical studies of oliceridine.</li><li>TRVN continues to expect to initiate a study to collect added QT interval data requested in the FDA's response letter during H1 2019, and it does not expect the absence of breakthrough therapy designation to impact the timing of FDA\u2019s review of the oliceridine new drug application following resubmission.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440982\" data-linked=\"Trevena -13% after FDA rescinds breakthrough designation for pain drug\" data-tweet=\"$TRVN - Trevena -13% after FDA rescinds breakthrough designation for pain drug https://seekingalpha.com/news/3440982-trevenaminus-13-after-fda-rescinds-breakthrough-designation-for-pain-drug?source=tweet\" data-url=\"https://seekingalpha.com/news/3440982-trevenaminus-13-after-fda-rescinds-breakthrough-designation-for-pain-drug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440977\" data-ts=\"1551996337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPLD\" target=\"_blank\">UPLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440977-upland-softwareplus-7-on-q4-beats-upside-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Upland Software +7% on Q4 beats, upside outlook</a></h4><ul><li>kUpland Software (NASDAQ:<a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software'>UPLD</a>) <font color=\"green\">gains 7.4%</font> after Q4 beats with 63% Y/Y revenue growth and upside Q1 guidance that has revenue from $47.9M to $48.9M (consensus: $46.4M).</li><li>Upside FY19 guidance has revenue of $194M to $198M (consensus: $190.35M).</li><li>Earnings call started at 5 PM ET with a webcast <a href=\"https://investor.uplandsoftware.com/\" target=\"_blank\">here.</a></li><li><a href=\"https://seekingalpha.com/pr/17437659-upland-software-reports-fourth-quarter-full-year-2018-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440866-upland-software-beats-0_09-beats-revenue\" target=\"_blank\">Upland Software beats by $0.09, beats on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440977\" data-linked=\"Upland Software +7% on Q4 beats, upside outlook\" data-tweet=\"$UPLD - Upland Software +7% on Q4 beats, upside outlook https://seekingalpha.com/news/3440977-upland-softwareplus-7-on-q4-beats-upside-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3440977-upland-softwareplus-7-on-q4-beats-upside-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440968\" data-ts=\"1551995824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICHR\" target=\"_blank\">ICHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440968-ichor-gets-buy-start-after-challenging-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ichor gets Buy start after challenging Q4</a></h4><ul><li>D.A. Davidson initiates Ichor (NASDAQ:<a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a>) with a Buy recommendation and $30 target, implying a 58% upside.</li><li>Last month, Ichor reported <a href=\"https://seekingalpha.com/news/3430496-ichor-minus-2-percent-challenging-q4\" target=\"_blank\">Q4 misses </a>due to \"more challenging\" market conditions than expected and guided downside Q1 results.</li><li>Ichor shares are <font color=\"green\">up 0.4%</font> after hours to $19.07.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440968\" data-linked=\"Ichor gets Buy start after challenging Q4\" data-tweet=\"$ICHR - Ichor gets Buy start after challenging Q4 https://seekingalpha.com/news/3440968-ichor-gets-buy-start-after-challenging-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3440968-ichor-gets-buy-start-after-challenging-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440961\" data-ts=\"1551995358\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUPV\" target=\"_blank\">SUPV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440961-grupo-supervielle-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Grupo Supervielle reports Q4 results</a></h4><ul><li>Grupo Supervielle (NYSE:<a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a>): Q4 GAAP EPS of AR$1.55.</li><li>Net interest income of AR$2.02B (-20.8% Y/Y)</li><li>Shares <font color=\"green\">+2.43%.</font></li><li><a href=\"https://seekingalpha.com/pr/17437815-grupo-supervielle-s-reports-4q18-consolidated-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440961\" data-linked=\"Grupo Supervielle reports Q4 results\" data-tweet=\"$SUPV - Grupo Supervielle reports Q4 results https://seekingalpha.com/news/3440961-grupo-supervielle-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3440961-grupo-supervielle-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440960\" data-ts=\"1551995355\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OKTA\" target=\"_blank\">OKTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440960-oktaminus-9-on-larger-net-loss-forecast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Okta -9% on larger net loss forecast</a></h4><ul><li>Okta (NASDAQ:<a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a>) <font color=\"red\">plunges 9%</font> after Q4 beats that came with mixed guidance and acquisition news.</li><li>The Q1 outlook has revenue from $116M to $117M (consensus: $111.8M) and EPS from -$0.22 to -$0.21 (consensus: -$0.12).</li><li>FY20 guidance has revenue from $530M to $535M (consensus: $518.33M) and EPS from -$0.53 to -$0.48 (consensus: -$0.24).</li><li>Acquisition: Okta acquires workflow automation startup Azuqua for $52.5M. The acquisition is expected to close in Q1.</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"https://investor.okta.com/\" target=\"_blank\">here.</a></li><li><a href=\"https://seekingalpha.com/pr/17437698-okta-announces-record-fourth-quarter-fiscal-year-2019-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440881-okta-beats-0_04-beats-revenue\" target=\"_blank\">Okta beats by $0.04, beats on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440960\" data-linked=\"Okta -9% on larger net loss forecast\" data-tweet=\"$OKTA - Okta -9% on larger net loss forecast https://seekingalpha.com/news/3440960-oktaminus-9-on-larger-net-loss-forecast?source=tweet\" data-url=\"https://seekingalpha.com/news/3440960-oktaminus-9-on-larger-net-loss-forecast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440950\" data-ts=\"1551994593\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTER\" target=\"_blank\">WTER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440950-alkaline-water-announces-public-offering-size-not-disclosed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alkaline Water announces public offering; size not disclosed</a></h4><ul><li>Alkaline Water (NASDAQ:<a href='https://seekingalpha.com/symbol/WTER' title='Alkaline Water Company Inc. &#40;The&#41;'>WTER</a>) <font color=\"red\">-14.4%</font> after-hours on news of a planned <a href=\"https://seekingalpha.com/pr/17437688-alkaline-water-company-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering</a> of unspecified size, with an underwriters option to purchase up to an additional 15% of common shares offered in the public offering.</li><li>WTER says it plans to use the proceeds for general corporate purposes, which may include reducing any outstanding indebtedness, increasing its working capital, or capital expenditures.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440950\" data-linked=\"Alkaline Water announces public offering; size not disclosed\" data-tweet=\"$WTER - Alkaline Water announces public offering; size not disclosed https://seekingalpha.com/news/3440950-alkaline-water-announces-public-offering-size-not-disclosed?source=tweet\" data-url=\"https://seekingalpha.com/news/3440950-alkaline-water-announces-public-offering-size-not-disclosed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>60&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440944\" data-ts=\"1551994376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GERN\" target=\"_blank\">GERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440944-geron-to-transfer-imetelstat-program-back-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Geron to transfer imetelstat program back by Q3</a></h4><ul><li>Geron (NASDAQ:<a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a>) <a href=\"https://seekingalpha.com/pr/17437718-geron-corporation-reports-fourth-quarter-full-year-2018-financial-results-recent-events\" target=\"_blank\">Q4 results</a> ($M): License fees/royalties: 0.4 (+96.3%).</li><li>Net loss: (7.3) (+1.7%); loss/share: (0.04) (+20.0%).</li><li><strong>2019 imetelstat milestones</strong>:</li><li>Transfer IND back to the company by next quarter and the clinical development program by Q3.</li><li>MDS indication: commence the Phase 3 portion of IMerge by mid-year. Phase 2 data to be presented at a medical conference.</li><li>MF indication: decide on late-stage development by end of Q3.</li><li>Shares are up <font color=\"green\">1%</font> after hours.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440883-geron-eps-line-beats-revenue\" target=\"_blank\">Geron EPS in-line, beats on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440944\" data-linked=\"Geron to transfer imetelstat program back by Q3\" data-tweet=\"$GERN - Geron to transfer imetelstat program back by Q3 https://seekingalpha.com/news/3440944-geron-to-transfer-imetelstat-program-back-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3440944-geron-to-transfer-imetelstat-program-back-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440937\" data-ts=\"1551994212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COST\" target=\"_blank\">COST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440937-costcoplus-2_8-after-q2-eps-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Costco +2.8% after Q2 EPS beat</a></h4><ul><li>Costco (NASDAQ:<a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a>) <font color=\"green\">gains 2.8%</font> after Q2 results that beat on EPS but missed on revenue despite a 7% Y/Y growth. Q2 membership fees were $768M.</li><li>Adjusted comps were up 6.7% for the total company in the quarter with the U.S. up 7.2%. E-commerce comps were up 25.5%.</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"https://www.costco.com/\" target=\"_blank\">here.</a></li><li><a href=\"https://seekingalpha.com/pr/17437786-costco-wholesale-corporation-reports-second-quarter-year-date-operating-results-fiscal-2019\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440909-costco-wholesale-beats-0_31-misses-revenue\" target=\"_blank\">Costco Wholesale beats by $0.31, misses on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440937\" data-linked=\"Costco +2.8% after Q2 EPS beat\" data-tweet=\"$COST - Costco +2.8% after Q2 EPS beat https://seekingalpha.com/news/3440937-costcoplus-2_8-after-q2-eps-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3440937-costcoplus-2_8-after-q2-eps-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440927\" data-ts=\"1551993891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYO\" target=\"_blank\">MYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440927-myomo-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myomo beats by $0.03, beats on revenue</a></h4><ul><li>Myomo (NYSEMKT:<a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a>): Q4 GAAP EPS of -$0.22 <span style=\"color:green\">beats by $0.03</span>.</li><li>Revenue of $0.89M (+61.8% Y/Y) <font color=\"green\">beats by $0.1M</font>.</li><li>Shares <font color=\"green\">+10%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17437723-myomo-reports-fourth-quarter-year-end-2018-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440927\" data-linked=\"Myomo beats by $0.03, beats on revenue\" data-tweet=\"$MYO - Myomo beats by $0.03, beats on revenue https://seekingalpha.com/news/3440927-myomo-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3440927-myomo-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440914\" data-ts=\"1551993509\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRVL\" target=\"_blank\">MRVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440914-marvellminus-4_5-on-mixed-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marvell -4.5% on mixed Q4</a></h4><ul><li>Marvell Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group, Ltd.'>MRVL</a>) <font color=\"red\">drops 4.5%</font> after hours on Q4 results that missed gross margin estimates with 64.5% versus 64.6%, EPS that missed by a cent at $0.25, and upside revenue at $745M (consensus: $740.49M).</li><li>Downside Q1 guidance has revenue from $630.5M to $669.5M (consensus: $725.22M) and EPS from continuing operations of $0.12 to $0.16. The company blames macro conditions for the Q1 guide and expects growth to continue in Q2.</li><li>Earnings call starts at 4:45 PM ET with a webcast <a href=\"https://investor.marvell.com/\" target=\"_blank\">here.</a></li><li><a href=\"https://seekingalpha.com/pr/17437736-marvell-technology-group-ltd-reports-fourth-quarter-fiscal-year-2019-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440885-marvell-technology-group-eps-line-beats-revenue\" target=\"_blank\">Marvell Technology Group EPS in-line, beats on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440914\" data-linked=\"Marvell -4.5% on mixed Q4\" data-tweet=\"$MRVL - Marvell -4.5% on mixed Q4 https://seekingalpha.com/news/3440914-marvellminus-4_5-on-mixed-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3440914-marvellminus-4_5-on-mixed-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440911\" data-ts=\"1551993481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTSO\" target=\"_blank\">CTSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440911-cytosorbents-misses-0_04-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cytosorbents misses by $0.04,  revenue in-line</a></h4><ul><li>Cytosorbents (NASDAQ:<a href='https://seekingalpha.com/symbol/CTSO' title='Cytosorbents Corp'>CTSO</a>): FY GAAP EPS of -$0.56 <span style=\"color:red\">misses by $0.04</span>.</li><li>Revenue of $22.5M (+48.5% Y/Y) in-line.</li><li>Shares <font color=\"green\">+1.06%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17437777-cytosorbents-achieves-record-revenue-product-sales-growth-2018\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440911\" data-linked=\"Cytosorbents misses by $0.04,  revenue in-line\" data-tweet=\"$CTSO - Cytosorbents misses by $0.04, revenue in-line https://seekingalpha.com/news/3440911-cytosorbents-misses-0_04-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3440911-cytosorbents-misses-0_04-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440901\" data-ts=\"1551993277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHUY\" target=\"_blank\">CHUY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440901-chuys-misses-0_01-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chuy&#39;s misses by $0.01, misses on revenue</a></h4><ul><li>Chuy's (NASDAQ:<a href='https://seekingalpha.com/symbol/CHUY' title='Chuy&#39;s Holdings'>CHUY</a>): Q4 Non-GAAP EPS of $0.11 <span style=\"color:red\">misses by $0.01</span>; GAAP EPS of $0.20 <span style=\"color:green\">beats by $0.08</span>.</li><li>Revenue of $96.84M (+0.9% Y/Y) <font color=\"red\">misses by $0.85M</font>.</li><li>Shares <font color=\"green\">+7%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17437700-chuy-s-holdings-inc-announces-fourth-quarter-fiscal-year-2018-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440901\" data-linked=\"Chuy&#39;s misses by $0.01, misses on revenue\" data-tweet=\"$CHUY - Chuy&#39;s misses by $0.01, misses on revenue https://seekingalpha.com/news/3440901-chuys-misses-0_01-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3440901-chuys-misses-0_01-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440883\" data-ts=\"1551992857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GERN\" target=\"_blank\">GERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440883-geron-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Geron EPS in-line, beats on revenue</a></h4><ul><li>Geron (NASDAQ:<a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a>): Q4 GAAP EPS of -$0.04 in-line.</li><li>Revenue of $0.38M (+100.0% Y/Y) <font color=\"green\">beats by $0.17M</font>.</li><li>Shares <font color=\"green\">+1.4%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17437718-geron-corporation-reports-fourth-quarter-full-year-2018-financial-results-recent-events\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440883\" data-linked=\"Geron EPS in-line, beats on revenue\" data-tweet=\"$GERN - Geron EPS in-line, beats on revenue https://seekingalpha.com/news/3440883-geron-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3440883-geron-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440873\" data-ts=\"1551992753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDXC\" target=\"_blank\">CDXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440873-chromadex-q4-sales-up-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ChromaDex Q4 sales up 20%</a></h4><ul><li>ChromaDex (NASDAQ:<a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a>) <a href=\"https://seekingalpha.com/pr/17437653-chromadex-corporation-reports-2018-financial-results\" target=\"_blank\">Q4 results</a> ($M): Sales: 9.1 (+20.0%).</li><li>Net loss: (8.2) (+6.8%); loss/share: (0.15) (+11.8%).</li><li>Expects to be cash flow breakeven in 2019.</li><li>Shares are down <font color=\"red\">1%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440873\" data-linked=\"ChromaDex Q4 sales up 20%\" data-tweet=\"$CDXC - ChromaDex Q4 sales up 20% https://seekingalpha.com/news/3440873-chromadex-q4-sales-up-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3440873-chromadex-q4-sales-up-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440860\" data-ts=\"1551991777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFFN\" target=\"_blank\">DFFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440860-diffusion-pharma-up-54\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diffusion Pharma up 54%</a></h4><ul><li>Thinly traded nano cap Diffusion Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color=\"green\">+53.5%</font>) is up on triple normal on no particular news. The stock has rallied <font color=\"green\">121%</font> since last week.</li><li>The company will report Q4 and 2018 results around the end of the month.</li><li>On the working capital front, at the end of September 2018 it had $11M in cash and equivalents while operations consumed $7.7M during the first three months of the year.</li><li>It has one clinical trial in process, a 22-subject Phase 3 trial (<a href=\"https://clinicaltrials.gov/ct2/show/NCT03393000?lead=diffusion+pharmaceuticals&amp;rank=2\" target=\"_blank\">INTACT</a>) evaluating lead drug trans sodium crocetinate &#40;TSC&#41; in newly-diagnosed glioblastoma patients. The estimated primary completion date is January 2021.</li><li>A 160-subject Phase 2 trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03763929?lead=diffusion+pharmaceuticals&amp;rank=1\" target=\"_blank\">PHAST-TSC</a>, evaluating TSC for the treatment of suspected stroke should commence shortly. The primary completion date is September 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440860\" data-linked=\"Diffusion Pharma up 54%\" data-tweet=\"$DFFN - Diffusion Pharma up 54% https://seekingalpha.com/news/3440860-diffusion-pharma-up-54?source=tweet\" data-url=\"https://seekingalpha.com/news/3440860-diffusion-pharma-up-54\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440858\" data-ts=\"1551991489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNQ\" target=\"_blank\">CNQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440858-canadian-natural-sees-government-mandatory-production-cuts-easing-this-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Natural sees government mandatory production cuts easing this year</a></h4><ul><li>Canadian Natural Resources (<a href='https://seekingalpha.com/symbol/CNQ' title='Canadian Natural Resources, Ltd.'>CNQ</a> <font color='green'>+2.4%</font>) says it expects the Alberta government to <a href=\"https://www.reuters.com/article/us-canadian-natural-results/canadian-natural-posts-fourth-quarter-loss-says-oil-prices-improving-idUSKCN1QO12N\" target=\"_blank\">ease mandatory oil production cuts</a> this year but could still delay new oil sands projects if the price of heavy crude falls.</li><li>Boosting crude-by-rail capacity, natural production declines and the Sturgeon refinery in Alberta ramping up heavy oil consumption means government curtailments could diminish markedly, but it is too early to say whether CNQ would start up its Kirby North and Primrose oil sands projects on schedule for later this year or delay, company president Tim McKay said during today's earnings conference call.</li><li>\"We have that optionality to look to defer if we see it\u2019s going to be a problem, if the differential is going to blow,\" McKay said.</li><li>BMO Capital analyst Randy Ollenberger views <a href=\"https://seekingalpha.com/news/3440648-canadian-natural-swings-q4-loss-says-canadian-crude-prices-improving\" target=\"_blank\">Q4 results</a> as \"a relative trough given particularly weak heavy oil pricing and anticipate higher free cash flow in coming quarters.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3440858\" data-linked=\"Canadian Natural sees government mandatory production cuts easing this year\" data-tweet=\"$CNQ - Canadian Natural sees government mandatory production cuts easing this year https://seekingalpha.com/news/3440858-canadian-natural-sees-government-mandatory-production-cuts-easing-this-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3440858-canadian-natural-sees-government-mandatory-production-cuts-easing-this-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440849\" data-ts=\"1551988794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440849-technology-movers-and-shakers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology movers and shakers</a></h4><ul><li><strong>Gainers: </strong>Rosetta Stone (NYSE:<a href='https://seekingalpha.com/symbol/RST' title='Rosetta Stone Inc.'>RST</a>) <font color=\"green\">+31%</font>. Communications Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/JCS' title='Communications Systems, Inc.'>JCS</a>) <font color=\"green\">+15%</font>. Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"green\">+15%</font>. Bandwidth (NASDAQ:<a href='https://seekingalpha.com/symbol/BAND' title='Bandwidth, Inc.'>BAND</a>) <font color=\"green\">+13%</font>. Ability (NASDAQ:<a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>CooTek (Cayman) (NYSE:<a href='https://seekingalpha.com/symbol/CTK' title='CooTek'>CTK</a>) <font color=\"red\">-18%</font>. Huami Corporation (NYSE:<a href='https://seekingalpha.com/symbol/HMI' title='Huami Corporation'>HMI</a>) <font color=\"red\">-13%</font>. China Finance Online (NASDAQ:<a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a>) <font color=\"red\">-13%</font>. Stratasys (NASDAQ:<a href='https://seekingalpha.com/symbol/SSYS' title='Stratasys, Inc.'>SSYS</a>) <font color=\"red\">-12%</font>. ACM Research (NASDAQ:<a href='https://seekingalpha.com/symbol/ACMR' title='ACM Research, Inc.'>ACMR</a>) <font color=\"red\">-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440849\" data-linked=\"Technology movers and shakers\" data-tweet=\"$RST $JCS $INPX - Technology movers and shakers https://seekingalpha.com/news/3440849-technology-movers-and-shakers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440849-technology-movers-and-shakers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440848\" data-ts=\"1551988063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440848-ge-stock-options-overly-optimistic-ahead-of-guidance-event-j-p-morgan-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE stock options &#39;overly optimistic&#39; ahead of guidance event, J.P. Morgan says</a></h4><ul><li>The next significant catalyst for General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='green'>+2.7%</font>) shares could be the March 14 event where the company will discuss its outlook, and J.P. Morgan derivatives strategist Shawn Quigg recommends using put-spread collars - buying put spreads while selling calls for zero cost - to <a href=\"https://finance.yahoo.com/news/jpmorgan-says-options-way-too-100159923.html\" target=\"_blank\">profit from too much optimism</a>.</li><li>GE shares \"are unlikely to breach $10 in the near term, owing to the company\u2019s <a href=\"https://seekingalpha.com/news/3439920-ges-culp-sees-negative-cash-flow-2019-power-unit-struggles\" target=\"_blank\">recent commentary</a> and fears of what may still lie ahead at the company\u2019s upcoming guidance update,\" Quigg's team writes. \"Meanwhile, the probability of the stock tracking back toward its December low appears to be rising.\"</li><li>Quigg says the option market is currently pricing in a post-GE Outlook move of ~9.2% in either direction, and options pricing had placed a 30% probability of a rally above $10/share, which he thinks is \"overly optimistic\" as well as am 18% probability of the stock falling back towards its lows below $7.50, a level Quigg believes is too conservative.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440848\" data-linked=\"GE stock options &#39;overly optimistic&#39; ahead of guidance event, J.P. Morgan says\" data-tweet=\"$GE - GE stock options &#39;overly optimistic&#39; ahead of guidance event, J.P. Morgan says https://seekingalpha.com/news/3440848-ge-stock-options-overly-optimistic-ahead-of-guidance-event-j-p-morgan-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3440848-ge-stock-options-overly-optimistic-ahead-of-guidance-event-j-p-morgan-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440847\" data-ts=\"1551987308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRTO\" target=\"_blank\">CRTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440847-criteo-appoints-nielsen-evp-to-board\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Criteo appoints Nielsen EVP to board</a></h4><ul><li>Criteo (NASDAQ:<a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a>) <a href=\"https://seekingalpha.com/pr/17437009-criteo-announces-appointment-marie-lalleman-board-directors\" target=\"_blank\">appoints</a> Nielsen EVP Marie Lalleman to its board, effective April 26.</li><li>The company also announces that independent director Sharon Fox Spielman will resign due to business commitments with her term ending on April 25.</li><li>Criteo shares are <font color=\"green\">up 1.4% </font>to $27.87.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440847\" data-linked=\"Criteo appoints Nielsen EVP to board\" data-tweet=\"$CRTO - Criteo appoints Nielsen EVP to board https://seekingalpha.com/news/3440847-criteo-appoints-nielsen-evp-to-board?source=tweet\" data-url=\"https://seekingalpha.com/news/3440847-criteo-appoints-nielsen-evp-to-board\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440842\" data-ts=\"1551986294\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440842-u-s-homebuilders-rise-amid-global-growth-worries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. homebuilders rise amid global growth worries</a></h4><ul><li>U.S. homebuilders stocks surge as the stock market wilts amid concern over slowing global economic growth, especially in Europe.</li><li>iShares U.S. Home Construction ETF (BATS:<a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>) <font color=\"green\">rises 1.2%</font> to $34.59, up 21% from Dec. 24, its lowest close in the past six months. (Keep in mind, it's 1-year return is still -13%).</li><li>Further, <a href=\"https://seekingalpha.com/news/3440775-u-s-mortgage-rates-rise\" target=\"_blank\">higher mortgage rates</a> didn't deter the advance.</li><li>Among the strongest performers in homebuilders today: D.R. Horton (<a href='https://seekingalpha.com/symbol/DHI' title='D. R. Horton Inc.'>DHI</a> <font color='green'>+3.1%</font>), Hovnanian (<a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a> <font color='green'>+3.3%</font>), Lennar (<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a> <font color='green'>+3.2%</font>), PulteGroup (<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a> <font color='green'>+2.8%</font>), and KB Home (<a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a> <font color='green'>+3%</font>).</li><li>Other real estate and REITs also provided some relief from a sea of red.</li><li>CBRE (<a href='https://seekingalpha.com/symbol/CBRE' title='CBRE Group, Inc.'>CBRE</a> <font color='green'>+1.2%</font>) issued guidance that exceeded consensus estimate for 2019.</li><li>Mall/shopping center REITs moving up include CBL (<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a> <font color='green'>+2.6%</font>), Pennsylvania REIT (<a href='https://seekingalpha.com/symbol/PEI' title='Pennsylvania Real Estate Investment Trust'>PEI</a> <font color='green'>+2.3%</font>), Kimco (<a href='https://seekingalpha.com/symbol/KIM' title='Kimco Realty Corporation'>KIM</a> <font color='green'>+1.2%</font>), SITE Centers (<a href='https://seekingalpha.com/symbol/SITC' title='SITE Centers Corp.'>SITC</a> <font color='green'>+1.2%</font>), and Seritage Growth Properties (<a href='https://seekingalpha.com/symbol/SRG' title='Seritage Growth Properties'>SRG</a> <font color='green'>+1.1%</font>).</li><li>Triple-net REITs Vereit (<a href='https://seekingalpha.com/symbol/VER' title='VEREIT Inc.'>VER</a> <font color='green'>+1.1%</font>), Store Capital (<a href='https://seekingalpha.com/symbol/STOR' title='STORE Capital'>STOR</a> <font color='green'>+1%</font>), and Spirit Realty (<a href='https://seekingalpha.com/symbol/SRC' title='Spirit Realty Capital'>SRC</a> <font color='green'>+1%</font>) exhibit strength as well as healthcare REITs Physicians Realty Trust (<a href='https://seekingalpha.com/symbol/DOC' title='Physicians Realty Trust'>DOC</a> <font color='green'>+1.2%</font>), Welltower (<a href='https://seekingalpha.com/symbol/WELL' title='Welltower Inc.'>WELL</a> <font color='green'>+1.1%</font>), Omega Healthcare (<a href='https://seekingalpha.com/symbol/OHI' title='Omega Healthcare Investors, Inc'>OHI</a> <font color='green'>+0.8%</font>), and Medical Properties Trust (<a href='https://seekingalpha.com/symbol/MPW' title='Medical Properties Trust, Inc.'>MPW</a> <font color='green'>+1.1%</font>).</li><li>ETFs: <a href='https://seekingalpha.com/symbol/VNQ' title='Vanguard Real Estate ETF'>VNQ</a>, <a href='https://seekingalpha.com/symbol/IYR' title='iShares U.S. Real Estate ETF'>IYR</a>, <a href='https://seekingalpha.com/symbol/XHB' title='SPDR Homebuilders ETF'>XHB</a>, <a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>, <a href='https://seekingalpha.com/symbol/RQI' title='Cohen&Steers Quality Income Realty Fund'>RQI</a>, <a href='https://seekingalpha.com/symbol/SCHH' title='Schwab U.S. REIT ETF'>SCHH</a>, <a href='https://seekingalpha.com/symbol/RNP' title='Cohen&Steers REIT&Preferred Income Fund'>RNP</a>, <a href='https://seekingalpha.com/symbol/RFI' title='Cohen&Steers Total Return Realty Fund'>RFI</a>, <a href='https://seekingalpha.com/symbol/KBWY' title='Invesco KBW Premium Yield Equity REIT Portfolio ETF'>KBWY</a>, <a href='https://seekingalpha.com/symbol/DRN' title='Direxion Daily Real Estate Bull 3x Shares ETF'>DRN</a>, <a href='https://seekingalpha.com/symbol/NRO' title='Neuberger Berman Real Estate Securities Income Fund'>NRO</a>, <a href='https://seekingalpha.com/symbol/URE' title='ProShares Ultra Real Estate ETF'>URE</a>, <a href='https://seekingalpha.com/symbol/ICF' title='iShares Cohen & Steers REIT ETF'>ICF</a>, <a href='https://seekingalpha.com/symbol/XLRE' title='Real Estate Select Sector SPDR ETF'>XLRE</a>, <a href='https://seekingalpha.com/symbol/JRS' title='Nuveen Real Estate Income Fund'>JRS</a>, <a href='https://seekingalpha.com/symbol/RWR' title='SPDR Dow Jones REIT ETF'>RWR</a>, <a href='https://seekingalpha.com/symbol/SRS' title='ProShares UltraShort Real Estate ETF'>SRS</a>, <a href='https://seekingalpha.com/symbol/FREL' title='Fidelity MSCI Real Estate Index ETF'>FREL</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440842\" data-linked=\"U.S. homebuilders rise amid global growth worries\" data-tweet=\"$ITB $DHI $HOV - U.S. homebuilders rise amid global growth worries https://seekingalpha.com/news/3440842-u-s-homebuilders-rise-amid-global-growth-worries?source=tweet\" data-url=\"https://seekingalpha.com/news/3440842-u-s-homebuilders-rise-amid-global-growth-worries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440841\" data-ts=\"1551986005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETSY\" target=\"_blank\">ETSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440841-etsyminus-4-after-updating-on-5-year-targets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Etsy -4% after updating on 5-year targets</a></h4><ul> <li>Etsy (NASDAQ:<a href='https://seekingalpha.com/symbol/ETSY' title='Etsy, Inc.'>ETSY</a>) updates investors on its five-year targets as part of the online retailer's first investor day event.</li><li>Etsy expects annual GMS to continue to grow in the range of 16% to 20% and revenue to grow slightly faster. Adjusted EBITDA margins are seen expanding to 30% or higher over that time frame.</li><li>Shares of Etsy are <font color=\"red\">down 3.88%</font> after being down as much as 5.10% earlier in the session.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17437394-etsy-provides-long-term-strategy-five-year-financial-targets-inaugural-investor-day\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440841\" data-linked=\"Etsy -4% after updating on 5-year targets\" data-tweet=\"$ETSY - Etsy -4% after updating on 5-year targets https://seekingalpha.com/news/3440841-etsyminus-4-after-updating-on-5-year-targets?source=tweet\" data-url=\"https://seekingalpha.com/news/3440841-etsyminus-4-after-updating-on-5-year-targets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440837\" data-ts=\"1551985178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440837-calumet-specialty-products-partners-and-ossen-innovation-among-energy-materials-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calumet Specialty Products Partners and Ossen Innovation among Energy/Materials gainers; Profire Energy and Torchlight Energy Resources among losers</a></h4><ul><li><b>Gainers: </b>Calumet Specialty Products Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a>) <font color=\"green\">+32%</font>. Ossen Innovation (NASDAQ:<a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a>) <font color=\"green\">+7%</font>. ION Geophysical (NYSE:<a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a>) <font color=\"green\">+6%</font>. Lithium Americas (NYSE:<a href='https://seekingalpha.com/symbol/LAC' title='Lithium Americas Corp.'>LAC</a>) <font color=\"green\">+6%</font>. Valhi (NYSE:<a href='https://seekingalpha.com/symbol/VHI' title='Valhi, Inc.'>VHI</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Profire Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/PFIE' title='Profire Energy, Inc.'>PFIE</a>) <font color=\"red\">-10%</font>. Torchlight Energy Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a>) <font color=\"red\">-9%</font>. Livent (NYSE:<a href='https://seekingalpha.com/symbol/LTHM' title='Livent'>LTHM</a>) <font color=\"red\">-8%</font>. Covia (NYSE:<a href='https://seekingalpha.com/symbol/CVIA' title='Covia Holdings Corporation'>CVIA</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440837\" data-linked=\"Calumet Specialty Products Partners and Ossen Innovation among Energy/Materials gainers; Profire Energy and Torchlight Energy Resources among losers\" data-tweet=\"$CLMT $OSN $IO - Calumet Specialty Products Partners and Ossen Innovation among Energy/Materials gainers; Profire Energy and Torchlight Energy Resources among losers https://seekingalpha.com/news/3440837-calumet-specialty-products-partners-and-ossen-innovation-among-energy-materials-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440837-calumet-specialty-products-partners-and-ossen-innovation-among-energy-materials-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440834\" data-ts=\"1551984031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NIO\" target=\"_blank\">NIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440834-nio-skids-lower-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nio skids lower again</a></h4><ul><li>The post-earnings slump for Nio (<a href='https://seekingalpha.com/symbol/NIO' title='NIO'>NIO</a> <font color='red'>-11.5%</font>) extends another day.</li><li>Not even a reinstated Buy rating from the desk of Goldman Sachs has been enough to end the skid.</li><li>Shares of Nio traded as low as $7.00 earlier in the session.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440199-nio-minus-16-percent-demand-slowdown\" target=\"_blank\">Nio -16% after demand slowdown</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440834\" data-linked=\"Nio skids lower again\" data-tweet=\"$NIO - Nio skids lower again https://seekingalpha.com/news/3440834-nio-skids-lower-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3440834-nio-skids-lower-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>93&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440832\" data-ts=\"1551983323\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNI\" target=\"_blank\">MNI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440832-mcclatchy-swings-to-loss-revenues-fall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McClatchy swings to loss as revenues fall</a></h4><ul>   <li>McClatchy (<a href=\"http://seekingalpha.com/symbol/MNI\" target=\"_blank\">MNI</a> <font color=\"red\">-2%</font>) <a href=\"https://seekingalpha.com/news/3440732-mcclatchy-reports-q4-results\" target=\"_blank\">swung to a loss</a> on an adjusted basis in Q4 on revenues that fell by double digits, though it held the typical newspaper pattern of digital growth against print declines.</li>    <li>Adjusted net loss was $0.9M vs. year-ago income of $12.4M. ON a GAAP basis, the loss was $27.5M, affected by after-tax noncash impairments on newspaper mastheads of $20.8M.</li>    <li>McClatchy made \"significant progress in our digital transformation,\" says CEO Craig Forman. Digital-only subscribers grew 51% Y/Y and 13.5% Q/Q, the 11th straight quarter of growth.</li>    <li>The company expects to see growth in total digital revenues (advertising and audience), while print ad revenues are expected to decline. Digital-only ad revenues should pass newspaper print advertising this year, it says.</li>    <li>Real estate sales will continue into this year, with equal or greater gross proceeds compared to 2018. Capex is forecast at $6M-$9M and there's a pension contribution requirement of about $3M ahead.</li>    <li><a href=\"https://seekingalpha.com/pr/17437042-mcclatchy-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3440832\" data-linked=\"McClatchy swings to loss as revenues fall\" data-tweet=\"$MNI - McClatchy swings to loss as revenues fall https://seekingalpha.com/news/3440832-mcclatchy-swings-to-loss-revenues-fall?source=tweet\" data-url=\"https://seekingalpha.com/news/3440832-mcclatchy-swings-to-loss-revenues-fall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440826\" data-ts=\"1551982364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440826-allergan-up-5-on-hopes-of-changes-after-rapastinel-flop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan up 5% on hopes of changes after rapastinel flop</a></h4><ul><li>Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color=\"green\">+4.8%</font>) is up on modestly higher volume following its <a href=\"https://seekingalpha.com/news/3440496-allergans-rapastinel-flunks-late-stage-mdd-studies-shares-5-percent-hours\" target=\"_blank\">Phase 3 flop</a> with MDD candidate rapastinel, normally a bearish event. Shares did sell off briefly, but have rebounded in apparent hopes that the setback will force the drugmaker to implement changes, which could include <a href=\"https://www.fiercepharma.com/pharma/allergan-investors-rooting-for-strategic-change-cheer-ph3-rapastinel-flop\" target=\"_blank\">spinning off its aesthetics business</a>, an option cited in a note to investors from Evercore ISI's Umer Raffat.</li><li>At a minimum, the pressure should ratchet up on Chairman, President &amp; CEO Brent Saunders to split his roles, a move <a href=\"https://seekingalpha.com/news/3434630-allergan-stiff-arms-appaloosa-chairman-ceo-split\" target=\"_blank\">advocated </a>by shareholder Appaloosa LP.</li><li><strong>Update</strong>: Appaloosa issued a <a href=\"https://seekingalpha.com/pr/17437317-appaloosa-issues-statement-regarding-allergan-s-failed-anti-depression-study\" target=\"_blank\">statement </a>reiterating its call for an independent chairman to \"rein in management's predilection for value destruction.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3440826\" data-linked=\"Allergan up 5% on hopes of changes after rapastinel flop\" data-tweet=\"$AGN - Allergan up 5% on hopes of changes after rapastinel flop https://seekingalpha.com/news/3440826-allergan-up-5-on-hopes-of-changes-after-rapastinel-flop?source=tweet\" data-url=\"https://seekingalpha.com/news/3440826-allergan-up-5-on-hopes-of-changes-after-rapastinel-flop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440823\" data-ts=\"1551981880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440823-broadway-financial-leads-financial-gainers-medley-management-and-yirendai-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadway Financial leads financial gainers; Medley Management and Yirendai  among losers</a></h4><ul><li><b>Gainers:</b> Broadway Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/BYFC' title='Broadway Financial Corporation'>BYFC</a>) <font color=\"green\">+15%</font>. Great Elm Capital Group (NYSE:<a href='https://seekingalpha.com/symbol/GEC' title='Great Elm Capital Group, Inc.'>GEC</a>) <font color=\"green\">+6%</font>. Trupanion (NYSE:<a href='https://seekingalpha.com/symbol/TRUP' title='Trupanion'>TRUP</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> LM Funding America (NASDAQ:<a href='https://seekingalpha.com/symbol/LMFA' title='LM Funding America, Inc.'>LMFA</a>) <font color=\"red\">-11%</font>. China HGS Real Estate (NASDAQ:<a href='https://seekingalpha.com/symbol/HGSH' title='China HGS Real Estate, Inc.'>HGSH</a>) <font color=\"red\">-9%</font>. Medley Management (NYSE:<a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management'>MDLY</a>) <font color=\"red\">-6%</font>. Yirendai (NYSE:<a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a>) <font color=\"red\">-5%</font>. CURO Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CURO' title='CURO Group Holdings Corp.'>CURO</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440823\" data-linked=\"Broadway Financial leads financial gainers; Medley Management and Yirendai  among losers\" data-tweet=\"$BYFC $GEC $TRUP - Broadway Financial leads financial gainers; Medley Management and Yirendai among losers https://seekingalpha.com/news/3440823-broadway-financial-leads-financial-gainers-medley-management-and-yirendai-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440823-broadway-financial-leads-financial-gainers-medley-management-and-yirendai-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440822\" data-ts=\"1551981753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDVT\" target=\"_blank\">RDVT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440822-red-violetminus-4_1-after-losses-narrow-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Violet -4.1% after losses narrow in Q4</a></h4><ul>   <li>Red Violet (NASDAQ:<a href='https://seekingalpha.com/symbol/RDVT' title='Red Violet, Inc.'>RDVT</a>) is <font color=\"red\">off 4.1%</font> after its <a href=\"https://seekingalpha.com/news/3440626-red-violet-reports-q4-results\" target=\"_blank\">Q4 results</a> today where revenue jumped and the company claimed \"substantial progress\" toward profitability.</li>    <li>Net loss narrowed by $1.1M, to $2M. And adjusted gross profit improved 186%, to $2.4M.</li>    <li>EBITDA improved by $1.1M to -$1M.</li>    <li>That's based on revenue gains of 74%.</li>    <li>\"We are seeing greater new customer adoption across all verticals and the first two months of this year indicate that 2019 will be a monumental year for red violet,\" says CEO Derek Dubner. \"We are as confident as ever in our path to positive cash flow and profitability.\u201d</li>    <li>Cash and equivalents came to $9.95M; net cash used in operations for the year was $8.05M.</li>    <li><a href=\"https://seekingalpha.com/pr/17436519-red-violet-announces-fourth-quarter-full-year-2018-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3440822\" data-linked=\"Red Violet -4.1% after losses narrow in Q4\" data-tweet=\"$RDVT - Red Violet -4.1% after losses narrow in Q4 https://seekingalpha.com/news/3440822-red-violetminus-4_1-after-losses-narrow-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3440822-red-violetminus-4_1-after-losses-narrow-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440821\" data-ts=\"1551981565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWI\" target=\"_blank\">TWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440821-titan-internationalminus-20-after-wide-q4-miss-tepid-2019-growth-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Titan International -20% after wide Q4 miss, tepid 2019 growth outlook</a></h4><ul><li>Titan International (<a href='https://seekingalpha.com/symbol/TWI' title='Titan International Inc.'>TWI</a> <font color='red'>-20.1%</font>) tumbles to its lowest level in three years after reporting a much larger than expected <a href=\"https://seekingalpha.com/news/3440604-titan-misses-0_16-misses-revenue\" target=\"_blank\">Q4 loss</a> and a 3.4% Y/Y revenue decline and guided for lighter than forecast 2019 overall net sales growth of 6%-7.5%.</li><li>Q4 net sales volume came in essentially flat compared to the year-ago quarter, with unfavorable currency translation hurting net sales by 5.4%, particularly in Latin America.</li><li>TWI says its disappointment that it did not achieve positive cash flow in 2018, despite earnings growth, owes to working capital increases - specifically inventory growth - and it will move forward with a focus on stronger strategic management of working capital and increased inventory turnover.</li><li>TWI says factors that weighed on FY 2018 results included the standoff over tariffs, rising steel prices and sluggish commodity prices, which impacted farmers. Revenue declines in the quarter resulted principally from decreased net sales in the agricultural and consumer segments.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440821\" data-linked=\"Titan International -20% after wide Q4 miss, tepid 2019 growth outlook\" data-tweet=\"$TWI - Titan International -20% after wide Q4 miss, tepid 2019 growth outlook https://seekingalpha.com/news/3440821-titan-internationalminus-20-after-wide-q4-miss-tepid-2019-growth-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3440821-titan-internationalminus-20-after-wide-q4-miss-tepid-2019-growth-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440820\" data-ts=\"1551981209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440820-healthcare-names-top-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare names top midday movers</a></h4><ul><li><strong>Gainers: </strong>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+201%</font>. Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics Inc'>SEEL</a>) <font color=\"green\">+79%</font>. ArQule (NASDAQ:<a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a>) <font color=\"green\">+66%</font>. Altimmune (NASDAQ:<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a>) <font color=\"green\">+60%</font>. Rosetta Stone (NYSE:<a href='https://seekingalpha.com/symbol/RST' title='Rosetta Stone Inc.'>RST</a>) <font color=\"green\">+31%</font>. Calumet Specialty Products Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a>) <font color=\"green\">+29%</font>. Cleveland BioLabs (NASDAQ:<a href='https://seekingalpha.com/symbol/CBLI' title='Cleveland BioLabs, Inc.'>CBLI</a>) <font color=\"green\">+26%</font>. Diffusion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a>) <font color=\"green\">+24%</font>. Pulmatrix (NASDAQ:<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a>) <font color=\"green\">+22%</font>. Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"green\">+20%</font>.</li> <li><strong>Losers: </strong>Aptevo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a>) <font color=\"red\">-42%</font>. Bridgepoint Education (NYSE:<a href='https://seekingalpha.com/symbol/BPI' title='Bridgepoint Education, Inc.'>BPI</a>) <font color=\"red\">-33%</font>. Resideo Technologies (NYSE:<a href='https://seekingalpha.com/symbol/REZI' title='Resideo Technologies, Inc.'>REZI</a>) <font color=\"red\">-27%</font>. Titan International (NYSE:<a href='https://seekingalpha.com/symbol/TWI' title='Titan International Inc.'>TWI</a>) <font color=\"red\">-21%</font>. Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) <font color=\"red\">-17%</font>. Hamilton Beach Brands Holding Company (NYSE:<a href='https://seekingalpha.com/symbol/HBB' title='Hamilton Beach Brands Holding Company'>HBB</a>) <font color=\"red\">-16%</font>. China SXT Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SXTC' title='China SXT Pharmaceuticals, Inc.'>SXTC</a>) <font color=\"red\">-14%</font>. Huami Corporation (NYSE:<a href='https://seekingalpha.com/symbol/HMI' title='Huami Corporation'>HMI</a>) <font color=\"red\">-14%</font>. CooTek (Cayman) (NYSE:<a href='https://seekingalpha.com/symbol/CTK' title='CooTek'>CTK</a>) <font color=\"red\">-14%</font>. Burlington Stores (NYSE:<a href='https://seekingalpha.com/symbol/BURL' title='Burlington Stores, Inc'>BURL</a>) <font color=\"red\">-14%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440820\" data-linked=\"Healthcare names top midday movers\" data-tweet=\"$BPTH $SEEL $ARQL - Healthcare names top midday movers https://seekingalpha.com/news/3440820-healthcare-names-top-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440820-healthcare-names-top-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440815\" data-ts=\"1551979056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPTH\" target=\"_blank\">BPTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440815-bio-path-up-174-on-prexigebersen-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bio-Path up 174% on prexigebersen data</a></h4><ul><li>Bio-Path Holdings (<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a> <font color=\"green\">+173.5%</font>) is the latest example that biotech is where the action is for intrepid investors. Shares have rocketed almost seven-fold since Tuesday, stoked by new <a href=\"https://seekingalpha.com/news/3440262-bio-path-54-percent-premarket-positive-prexigebersen-data\" target=\"_blank\">mid-stage data</a> on prexigebersen in AML. Shares are up 15-fold since closing at $2.02 on February 27.</li><li>The intraday high today is a whopping $73.52 (great example of the potential risk of a market buy order in a surging stock).</li></ul><div class=\"tiny-share-widget\" data-id=\"3440815\" data-linked=\"Bio-Path up 174% on prexigebersen data\" data-tweet=\"$BPTH - Bio-Path up 174% on prexigebersen data https://seekingalpha.com/news/3440815-bio-path-up-174-on-prexigebersen-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3440815-bio-path-up-174-on-prexigebersen-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440810\" data-ts=\"1551978209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440810-ballantyne-strong-leads-consumer-gainers-craft-brew-alliance-and-nio-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ballantyne Strong leads consumer gainers; Craft Brew Alliance and NIO among the losers</a></h4><ul><li><b>Gainers: </b>Ballantyne Strong (NYSEMKT:<a href='https://seekingalpha.com/symbol/BTN' title='Ballantyne Strong, Inc.'>BTN</a>) <font color=\"green\">+26%</font>. REV Group (NYSE:<a href='https://seekingalpha.com/symbol/REVG' title='REV Group'>REVG</a>) <font color=\"green\">+11%</font>. Superior Industries International (NYSE:<a href='https://seekingalpha.com/symbol/SUP' title='Superior Industries International Inc.'>SUP</a>) <font color=\"green\">+9%</font>. Sequential Brands Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a>) <font color=\"green\">+8%</font>.  Viomi Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/VIOT' title='Viomi Technology'>VIOT</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Hamilton Beach Brands (NYSE:<a href='https://seekingalpha.com/symbol/HBB' title='Hamilton Beach Brands Holding Company'>HBB</a>) <font color=\"red\">-18%</font>. NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO'>NIO</a>) <font color=\"red\">-11%</font>. TDH Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a>) <font color=\"red\">-10%</font>. Craft Brew Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/BREW' title='Craft Brew Alliance Inc'>BREW</a>) <font color=\"red\">-6%</font>. Pingtan Marine Enterprise (NASDAQ:<a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440810\" data-linked=\"Ballantyne Strong leads consumer gainers; Craft Brew Alliance and NIO among the losers\" data-tweet=\"$BTN $REVG $SUP - Ballantyne Strong leads consumer gainers; Craft Brew Alliance and NIO among the losers https://seekingalpha.com/news/3440810-ballantyne-strong-leads-consumer-gainers-craft-brew-alliance-and-nio-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440810-ballantyne-strong-leads-consumer-gainers-craft-brew-alliance-and-nio-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440809\" data-ts=\"1551977851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFRG\" target=\"_blank\">DFRG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440809-del-friscosplus-4-on-report-of-potential-split-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Del Frisco&#39;s +4% on report of potential split sale</a></h4><ul> <li>Sources tell <em>The Deal</em> that there is a \"good chance\" that Del Frisco's Restaurant Group (<a href='https://seekingalpha.com/symbol/DFRG' title='Del Frisco&#39;s Restaurant Group'>DFRG</a> <font color='green'>+4.1%</font>) could <a href=\"https://twitter.com/TheDealNewsroom/status/1103697034501124096\" target=\"_blank\">sell</a> its upscale steakhouse operation to a  single bidder and the Barteca Restaurant Group to a different party.</li> <li>The restaurant company launched a strategic review in December.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3440809\" data-linked=\"Del Frisco&#39;s +4% on report of potential split sale\" data-tweet=\"$DFRG - Del Frisco&#39;s +4% on report of potential split sale https://seekingalpha.com/news/3440809-del-friscosplus-4-on-report-of-potential-split-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3440809-del-friscosplus-4-on-report-of-potential-split-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440806\" data-ts=\"1551977433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPG\" target=\"_blank\">CPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440806-crescent-point-energyminus-6-after-taking-2b-writedown\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crescent Point Energy -6% after taking $2B writedown</a></h4><ul><li>Crescent Point Energy (<a href='https://seekingalpha.com/symbol/CPG' title='Crescent Point Energy Corp'>CPG</a> <font color=\"red\">-5.8%</font>) tumbles after <a href=\"https://seekingalpha.com/news/3440714-crescent-point-rises-despite-missing-q4-earnings-production-estimates\" target=\"_blank\">missing estimates</a> on Q4 earnings and production, and writes down the value of its assets by C$2.73B (~US$2B) and saying it will offer to sell more holdings as new CEO Craig Bryksa targets core operations.</li><li>CPG has not announced a major acquisition in more than two years, but a key benchmark of its cost to develop new resources came in at C$23.64/bbl in 2018, 12% above its three-year average, and Raymond James analyst Chris Cox says investors will need to see the company\u2019s new leadership make more progress on that front before they can appreciate its quarterly results and cash flows.</li><li>\"The Street will struggle to gain confidence that the company has meaningfully turned the corner with respect to improvements in capital efficiency, [but] we would note that many of the improvements employed under the new leadership were not fully implemented until later in the year,\" Cox writes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440806\" data-linked=\"Crescent Point Energy -6% after taking $2B writedown\" data-tweet=\"$CPG - Crescent Point Energy -6% after taking $2B writedown https://seekingalpha.com/news/3440806-crescent-point-energyminus-6-after-taking-2b-writedown?source=tweet\" data-url=\"https://seekingalpha.com/news/3440806-crescent-point-energyminus-6-after-taking-2b-writedown\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440799\" data-ts=\"1551976272\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440799-reuters-altice-usa-mulls-sale-of-lightpath-fiber-unit-sharesplus-2_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Altice USA mulls sale of Lightpath fiber unit; shares +2.3%</a></h4><ul>   <li>Altice USA (NYSE:<a href='https://seekingalpha.com/symbol/ATUS' title='Altice USA'>ATUS</a>) is considering a <a href=\"https://www.reuters.com/article/us-altice-usa-divestiture/altice-usa-is-considering-sale-of-lightpath-fiber-unit-sources-idUSKCN1QO21Z?il=0\" target=\"_blank\">sale of its Lightpath fiber unit</a>, a transaction that could bring $3B, Reuters reports.</li>    <li>Shares are <font color=\"green\">up 2.3%</font> to a session high.</li>    <li>The cableco has hired Goldman Sachs to review options for the unit, which include bringing in an investor rather than disposing of Lightpath entirely.</li>    <li>CEO Dexter Goei said at an investor conference in December that the unit was \"non-strategic\" and might be better off in other hands or \"at least partnered up with someone.\"</li>    <li>Such a move would follow in the footsteps of former parent Altice Europe (<a href='https://seekingalpha.com/symbol/ATCEY' title='ALTICE S A ADR'>OTCPK:ATCEY</a>), which sold a 49.99% stake in its fiber-optic business last November for $2.05B, and raised some \u20ac4B in cash through sales of stakes in its towers businesses in France and Portugal.</li>    <li>Lightpath EBITDA is more than $200M/year, according to the report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440799\" data-linked=\"Reuters: Altice USA mulls sale of Lightpath fiber unit; shares +2.3%\" data-tweet=\"$ATUS $ATCEY $ALLVF - Reuters: Altice USA mulls sale of Lightpath fiber unit; shares +2.3% https://seekingalpha.com/news/3440799-reuters-altice-usa-mulls-sale-of-lightpath-fiber-unit-sharesplus-2_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3440799-reuters-altice-usa-mulls-sale-of-lightpath-fiber-unit-sharesplus-2_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440798\" data-ts=\"1551975920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EUFN\" target=\"_blank\">EUFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440798-bank-stocks-slump-amid-ecbs-dimmed-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank stocks slump amid ECB&#39;s dimmed outlook</a></h4><ul><li>The European Central Bank's dimmer outlook for the eurozone growth and lengthened timeline for when its next rate hike might occur are leading bank stocks lower, with, of course, Europe-based banks bearing the brunt.</li><li>The iShares MSCI Europe Financials Sector Index ETF (NASDAQ:<a href='https://seekingalpha.com/symbol/EUFN' title='iShares MSCI Europe Financials Sector Index ETF'>EUFN</a>) <font color=\"red\">sinks 2.3%</font>.</li><li>Deutsche Bank (NYSE:<a href='https://seekingalpha.com/symbol/DB' title='Deutsche Bank AG'>DB</a>), Germany's biggest lender, <font color=\"red\">slides 4.9%</font>; if that decline holds, it would be Deutsche's biggest one-day decline in a month.</li><li>Among other banks feeling the pain: Banco Santander (<a href='https://seekingalpha.com/symbol/SAN' title='Banco Santander S.A.'>SAN</a> <font color='red'>-4%</font>), UBS Group (<a href='https://seekingalpha.com/symbol/UBS' title='UBS Group AG'>UBS</a> <font color='red'>-2.3%</font>), ING Groep (<a href='https://seekingalpha.com/symbol/ING' title='ING Groep N.V.'>ING</a> <font color='red'>-2.5%</font>), and Credit Suisse (<a href='https://seekingalpha.com/symbol/CS' title='Credit Suisse Group AG'>CS</a> <font color='red'>-2.1%</font>).</li><li>U.S. financials are also caught up in the downdraft, bringing the Financial Select Sector SPDR ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>)<font color=\"red\"> down 1.3%</font>.</li><li>Among U.S. megabanks, Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='red'>-1.5%</font>), Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-1.4%</font>), Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='red'>-1.4%</font>), and Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-1.3%</font>) all saw shares fall more than 1%.</li><li>Meanwhile, the Dollar Index <font color=\"green\">strengthens 0.5%</font> to 97.39 and the 10-year Treasury rallies, pushing yield down 4 basis points to 2.65%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440730-euro-droops-ecb-cuts-2019-euro-zone-outlook\" target=\"_blank\">Euro droops as  ECB cuts 2019 euro zone outlook</a> (March 7)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/EUFN' title='iShares MSCI Europe Financials Sector Index ETF'>EUFN</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Invesco S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, <a href='https://seekingalpha.com/symbol/RWW' title='Oppenheimer Financials Sector Revenue ETF'>RWW</a>, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/EUFL' title='Direxion Daily European Financials Bull 2X Shares ETF'>EUFL</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440798\" data-linked=\"Bank stocks slump amid ECB&#39;s dimmed outlook\" data-tweet=\"$EUFN $DB $SAN - Bank stocks slump amid ECB&#39;s dimmed outlook https://seekingalpha.com/news/3440798-bank-stocks-slump-amid-ecbs-dimmed-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3440798-bank-stocks-slump-amid-ecbs-dimmed-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440797\" data-ts=\"1551975673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEET\" target=\"_blank\">MEET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440797-meet-group-gains-on-canaccords-pt-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Meet Group gains on Canaccord&#39;s PT raise</a></h4><ul><li>Canaccord Genuity maintains a Buy rating on Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) and raises its target by a dollar to $8 after yesterday's <a href=\"https://seekingalpha.com/news/3440225-meet-group-beats-q4-acquires-growlr\" target=\"_blank\">earnings report</a>.</li><li>The firm says it's \"finding it difficult to find things not to like\" and particularly likes the company's video monetization story.</li><li>Canaccord estimates a five-year EBITDA CAGR of 18% over its revenue CAGR of 13%.</li><li>MEET shares are <font color=\"green\">up 0.7%</font> to $5.52.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440797\" data-linked=\"Meet Group gains on Canaccord&#39;s PT raise\" data-tweet=\"$MEET - Meet Group gains on Canaccord&#39;s PT raise https://seekingalpha.com/news/3440797-meet-group-gains-on-canaccords-pt-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3440797-meet-group-gains-on-canaccords-pt-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440792\" data-ts=\"1551974837\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440792-seelos-therapeutics-and-bio-path-holdings-among-healthcare-gainers-aptevo-therapeutics-leads\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seelos Therapeutics and Bio-Path Holdings among healthcare gainers; Aptevo Therapeutics leads the losers</a></h4><ul><li><b>Gainers: </b>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+294%</font>. Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics Inc'>SEEL</a>) <font color=\"green\">+96%</font>. ArQule (NASDAQ:<a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a>) <font color=\"green\">+42%</font>. Cleveland BioLabs (NASDAQ:<a href='https://seekingalpha.com/symbol/CBLI' title='Cleveland BioLabs, Inc.'>CBLI</a>) <font color=\"green\">+26%</font>. Altimmune (NASDAQ:<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a>) <font color=\"green\">+25%</font>.</li><li><b>Losers: </b>Aptevo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a>) <font color=\"red\">-43%</font>. Kindred Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/KIN' title='Kindred Biosciences, Inc.'>KIN</a>) <font color=\"red\">-13%</font>. China SXT Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SXTC' title='China SXT Pharmaceuticals, Inc.'>SXTC</a>) <font color=\"red\">-13%</font>. Aptinyx (NASDAQ:<a href='https://seekingalpha.com/symbol/APTX' title='Aptinyx'>APTX</a>) <font color=\"red\">-12%</font>. India Globalization Capital (<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440792\" data-linked=\"Seelos Therapeutics and Bio-Path Holdings among healthcare gainers; Aptevo Therapeutics leads the losers\" data-tweet=\"$BPTH $SEEL $ARQL - Seelos Therapeutics and Bio-Path Holdings among healthcare gainers; Aptevo Therapeutics leads the losers https://seekingalpha.com/news/3440792-seelos-therapeutics-and-bio-path-holdings-among-healthcare-gainers-aptevo-therapeutics-leads?source=tweet\" data-url=\"https://seekingalpha.com/news/3440792-seelos-therapeutics-and-bio-path-holdings-among-healthcare-gainers-aptevo-therapeutics-leads\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440790\" data-ts=\"1551974762\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPI\" target=\"_blank\">BPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440790-bridgepoint-educationminus-36-after-preliminary-q4-results-restatements\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bridgepoint Education -36% after preliminary Q4 results, restatements</a></h4><ul> <li>Bridgepoint Education (NYSE:<a href='https://seekingalpha.com/symbol/BPI' title='Bridgepoint Education, Inc.'>BPI</a>) is in freefall after the company reports preliminary Q4 results below estimates and discloses that it will restate results for the 3-month and 9-month periods ending on September.</li> <li>The company announces preliminary Q4 revenue of $93.7M to $94.7M vs. $102M consensus and EPS of -$0.23 to -$0.25 vs. -$0.12.</li> <li>Shares of BPI are <font color=\"red\">down 35.5%</font> to trade at their lowest level since last May.</li><li><a href=\"https://seekingalpha.com/filing/4393442\" target=\"_blank\">SEC Form 8-K</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3440790\" data-linked=\"Bridgepoint Education -36% after preliminary Q4 results, restatements\" data-tweet=\"$BPI $ZVO - Bridgepoint Education -36% after preliminary Q4 results, restatements https://seekingalpha.com/news/3440790-bridgepoint-educationminus-36-after-preliminary-q4-results-restatements?source=tweet\" data-url=\"https://seekingalpha.com/news/3440790-bridgepoint-educationminus-36-after-preliminary-q4-results-restatements\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440789\" data-ts=\"1551974750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBLI\" target=\"_blank\">CBLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440789-cleveland-biolabs-up-27-on-advancement-of-entolimod-application\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cleveland BioLabs up 27% on advancement of entolimod application</a></h4><ul><li>Ultra-thinly traded nano cap Cleveland BioLabs (<a href='https://seekingalpha.com/symbol/CBLI' title='Cleveland BioLabs, Inc.'>CBLI</a> <font color=\"green\">+27.3%</font>) is up on almost a 10x surge in volume, albeit on turnover of only 78K shares, in apparent response to its <a href=\"https://seekingalpha.com/pr/17436830-cleveland-biolabs-reports-2018-financial-results-development-progress\" target=\"_blank\">update </a>on its U.S. emergency use application for entolimod.</li><li>The company has requested a meeting with the FDA to review the data from a non-human primate study assessing the formulations of entolimod used in previously conducted trials and the proposed formulation for commercialization under Emergency Use Authorization status in addition certain aspects of the chemistry, manufacturing and controls &#40;CMC&#41; information. It expects the agency to proceed with its review of additional parts of the application after the meeting.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440789\" data-linked=\"Cleveland BioLabs up 27% on advancement of entolimod application\" data-tweet=\"$CBLI - Cleveland BioLabs up 27% on advancement of entolimod application https://seekingalpha.com/news/3440789-cleveland-biolabs-up-27-on-advancement-of-entolimod-application?source=tweet\" data-url=\"https://seekingalpha.com/news/3440789-cleveland-biolabs-up-27-on-advancement-of-entolimod-application\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440785\" data-ts=\"1551973990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TECD\" target=\"_blank\">TECD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440785-tech-dataminus-9-on-mixed-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech Data -9% on mixed outlook</a></h4><ul><li>Tech Data (NASDAQ:<a href='https://seekingalpha.com/symbol/TECD' title='Tech Data Corporation'>TECD</a>) <font color=\"red\">drops 9.3%</font> after a mixed Q4 report that beat on EPS and missed on revenue. The Q1 guidance has downside revenue from $8.3B to $8.6B (consensus: $8.69B) and in-line EPS from $1.80 to $2.10 (consensus: $2.04).</li><li>Buyback: The board adds $100M to the existing repurchase program, bringing the total up to $300M.</li><li><a href=\"https://seekingalpha.com/pr/17436462-tech-data-corporation-reports-fourth-quarter-fiscal-year-2019-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440602-tech-data-beats-0_52-misses-revenue\" target=\"_blank\">Tech Data beats by $0.52, misses on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440785\" data-linked=\"Tech Data -9% on mixed outlook\" data-tweet=\"$TECD - Tech Data -9% on mixed outlook https://seekingalpha.com/news/3440785-tech-dataminus-9-on-mixed-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3440785-tech-dataminus-9-on-mixed-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440784\" data-ts=\"1551973791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HRB\" target=\"_blank\">HRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440784-h-and-r-blockplus-4_9-fiscal-q3-top-line-falls-less-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">H&amp;R Block +4.9% as fiscal Q3 top line falls less than expected</a></h4><ul><li>H&amp;R Block (NYSE:<a href='https://seekingalpha.com/symbol/HRB' title='H&R Block Inc.'>HRB</a>)<font color=\"green\"> jumps 4.9% </font>after <a href=\"https://seekingalpha.com/pr/17436838-h-and-r-block-announces-fiscal-2019-third-quarter-results-reiterates-financial-outlook-fiscal\" target=\"_blank\">fiscal Q3 revenue</a> of $468.4M beat the average analyst estimate of $465.5M.</li><li>Q3's top line fell by 4% from a year ago, primarily due to a delay in overall industry filings.</li><li>Q3 loss from continuing operations of 58 cents per share, missed consensus estimate by 1 cent, and improved from a loss $1.16 in the year-ago quarter.</li><li>Reiterates FY2019 outlook of $3.05B-$3.10B of revenue and EBITDA margin of 24%-26%.</li><li>For 2019 tax season, HRB sees client growth in H2 with declining net average charge in its assisted business and higher net average charge due to improved mix in DIY business.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440696-h-and-amp-r-block-misses-0_01-beats-revenue\" target=\"_blank\">H&amp;R Block misses by $0.01, beats on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440784\" data-linked=\"H&amp;R Block +4.9% as fiscal Q3 top line falls less than expected\" data-tweet=\"$HRB - H&amp;R Block +4.9% as fiscal Q3 top line falls less than expected https://seekingalpha.com/news/3440784-h-and-r-blockplus-4_9-fiscal-q3-top-line-falls-less-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3440784-h-and-r-blockplus-4_9-fiscal-q3-top-line-falls-less-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440779\" data-ts=\"1551973104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGE\" target=\"_blank\">AGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440779-agex-up-1-on-icarbonx-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AgeX up 1% on iCarbonX collaboration</a></h4><ul><li>Thinly traded micro cap AgeX Therapeutics (<a href='https://seekingalpha.com/symbol/AGE' title='AgeX Therapeutics Inc'>AGE</a> <font color=\"green\">+1.2%</font>) is up on below-average volume on subsidiary LifeMap Sciences' <a href=\"https://seekingalpha.com/pr/17436540-lifemap-sciences-icarbonx-research-shenzhen-announce-strategic-collaboration\" target=\"_blank\">collaboration </a>with iCarbonX Research Shenzhen leveraging LifeMap's GeneCards Suite platform in product prototype design and scientific research.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440779\" data-linked=\"AgeX up 1% on iCarbonX collaboration\" data-tweet=\"$AGE - AgeX up 1% on iCarbonX collaboration https://seekingalpha.com/news/3440779-agex-up-1-on-icarbonx-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3440779-agex-up-1-on-icarbonx-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440778\" data-ts=\"1551972945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MANU\" target=\"_blank\">MANU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440778-manchester-unitedplus-5-after-shock-win\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Manchester United +5% after shock win</a></h4><ul> <li>Manchester United (NYSE:<a href='https://seekingalpha.com/symbol/MANU' title='Manchester United Ltd.'>MANU</a>) <font color=\"green\">shoots up 5.33%</font> in morning trading after a <a href=\"https://www.skysports.com/football/news/11667/11657225/manchester-united-player-ratings-verdict-after-psg-are-stunned-in-champions-league\" target=\"_blank\">shock result</a> in the club's Champions League match yesterday.</li> <li>The soccer club won 3-1 in Paris to overcome a 2-0 home loss deficit to advance to the quarterfinals on the away goals tiebreaker. Man U achieved the feat with ten players missing due to suspension or injury. The extra Champions League matches will lead to additional Q2 revenue for Manchester United above what analysts had forecast.</li> <li>Shares of Manchester United are up 20% over the last 90 days as the team has moved to 4th in the Premier League behind Manchester City, Liverpool and Tottenham. A 4th place finish would be good enough for Champions League inclusion and the lucrative payday that follows.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440778\" data-linked=\"Manchester United +5% after shock win\" data-tweet=\"$MANU - Manchester United +5% after shock win https://seekingalpha.com/news/3440778-manchester-unitedplus-5-after-shock-win?source=tweet\" data-url=\"https://seekingalpha.com/news/3440778-manchester-unitedplus-5-after-shock-win\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440776\" data-ts=\"1551972653\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440776-natural-gas-inventory-draw-slightly-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory draw slightly more than consensus</a></h4><ul><li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory:</a> <strong>-149 Bcf</strong> vs. -141 Bcf consensus, -166 Bcf last week.</li><li>Futures <font color=\"green\">+0.63%</font> to $2.859.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440776\" data-linked=\"Natural gas inventory draw slightly more than consensus\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory draw slightly more than consensus https://seekingalpha.com/news/3440776-natural-gas-inventory-draw-slightly-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3440776-natural-gas-inventory-draw-slightly-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440774\" data-ts=\"1551972367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440774-pg-and-e-considers-hiking-pay-for-new-board-members-to-400k-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E considers hiking pay for new board members to $400K - Bloomberg</a></h4><ul><li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='green'>+3.4%</font>) is considering offering new board members <a href=\"https://finance.yahoo.com/news/pg-e-considers-boosting-director-220712586.html\" target=\"_blank\">significantly higher compensation</a> than existing directors as the bankrupt utility seeks to recruit directors, Bloomberg reports.</li><li>The company would like to offer incoming directors as much as $400K/year to reflect how the role would require a greater time commitment than the typical utility board seat, according to the report, which also says a PG&amp;E director was compensated an average of $271K in 2017.</li><li>Companies going through a bankruptcy frequently ask a judge to pass new bonus programs for executives or raise director pay since salvaging a bankrupt company is so difficult.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440774\" data-linked=\"PG&amp;E considers hiking pay for new board members to $400K - Bloomberg\" data-tweet=\"$PCG - PG&amp;E considers hiking pay for new board members to $400K - Bloomberg https://seekingalpha.com/news/3440774-pg-and-e-considers-hiking-pay-for-new-board-members-to-400k-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3440774-pg-and-e-considers-hiking-pay-for-new-board-members-to-400k-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440772\" data-ts=\"1551972263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XNET\" target=\"_blank\">XNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440772-xunleiminus-11-after-revenue-tumble-wider-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xunlei -11% after revenue tumble, wider loss</a></h4><ul>   <li>Xunlei (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>) is <font color=\"red\">11.3% lower</font> today after its <a href=\"https://seekingalpha.com/news/3440601-xunlei-reports-q4-results\" target=\"_blank\">Q4 results</a> showed sliding revenues and sharp new losses.</li>    <li>Gross profit fell 21.4% from the previous quarter, to $18.7M, and net loss widened to $32.4M from last quarter's loss of $15.9M.</li>    <li>Revenue fell both Y/Y (by 49%) and sequentially (by 6.6%), to $42.3M.</li>    <li>Operating loss was $29.8M, vs. the previous quarter's loss of $18.2M, mainly due to the revenue decline and a one-off asset impairment.</li>    <li>Revenue breakout: Cloud computing and other Internet VAS, $18.1M; Subscription, $18.2M; Online advertising, $6M.</li>    <li>For Q1, it's guiding to $39M-$43M, which would indicate another Q/Q drop (of about 3.1%).</li>    <li><a href=\"https://seekingalpha.com/pr/17436440-xunlei-announces-unaudited-financial-results-fourth-quarter-fiscal-year-ended-december-31\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3440772\" data-linked=\"Xunlei -11% after revenue tumble, wider loss\" data-tweet=\"$XNET - Xunlei -11% after revenue tumble, wider loss https://seekingalpha.com/news/3440772-xunleiminus-11-after-revenue-tumble-wider-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3440772-xunleiminus-11-after-revenue-tumble-wider-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440771\" data-ts=\"1551971712\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPSN\" target=\"_blank\">LPSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440771-livepersonplus-1_8-on-evercore-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LivePerson +1.8% on Evercore initiation</a></h4><ul><li>Evercore starts LivePerson (NASDAQ:<a href='https://seekingalpha.com/symbol/LPSN' title='LivePerson, Inc.'>LPSN</a>) at Outperform with a $34 price target seeing it as one of the better-positioned small-cap vendors benefiting from broader digital transformation trends.</li><li>Evercore says LivePerson's text channel is in-line with the demographic shift away from voice communications while its new LiveEngage platform could help accelerate growth above 2020 targets.</li><li>LivePerson shares are <font color=\"green\">up 1.8%</font> to $26.80.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440771\" data-linked=\"LivePerson +1.8% on Evercore initiation\" data-tweet=\"$LPSN - LivePerson +1.8% on Evercore initiation https://seekingalpha.com/news/3440771-livepersonplus-1_8-on-evercore-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3440771-livepersonplus-1_8-on-evercore-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440770\" data-ts=\"1551971678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLLI\" target=\"_blank\">OLLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440770-ollies-bargain-outlet-holdingsminus-3-after-negative-mention\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ollie&#39;s Bargain Outlet Holdings -3% after negative mention</a></h4><ul> <li>Grant's Interest Rate Observer has reportedly <a href=\"https://www.streetinsider.com/Analyst+Comments/Ollies+Bargain+Outlet+%28OLLI%29+Mentioned+Cautiously+at+Grants/15230701.html\" target=\"_blank\">published</a> an article on Ollie's Bargain Outlet Holdings (<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings'>OLLI</a> <font color='red'>-2.6%</font>) that includes a warning on \"accounting problems\" with how inventory and margins were reported.</li> <li>Ollie's is expected to report Q4 results later this month after posting a holiday sales update in January.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3440770\" data-linked=\"Ollie&#39;s Bargain Outlet Holdings -3% after negative mention\" data-tweet=\"$OLLI - Ollie&#39;s Bargain Outlet Holdings -3% after negative mention https://seekingalpha.com/news/3440770-ollies-bargain-outlet-holdingsminus-3-after-negative-mention?source=tweet\" data-url=\"https://seekingalpha.com/news/3440770-ollies-bargain-outlet-holdingsminus-3-after-negative-mention\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440768\" data-ts=\"1551971533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APVO\" target=\"_blank\">APVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440768-aptevo-down-45-on-pricing-of-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptevo down 45% on pricing of equity offering</a></h4><ul><li>Aptevo Therapeutics (<a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color=\"red\">-45.1%</font>) slumps on almost 13x higher volume in response to its <a href=\"https://seekingalpha.com/pr/17437109-aptevo-announces-pricing-22-million-offering-common-stock-warrants\" target=\"_blank\">public offering</a> of 19.85M shares of common stock and warrants to purchase up to the same number of shares at a price of $1.00 per share and warrant.</li><li>The company is also offering pre-funded warrants to purchase up to 2.15M common shares at $0.01 per share and related warrants to purchase up to 2.15M common shares at $1.30 at a combined price of $0.99.</li><li>Total gross proceeds should be ~$22.00M. Closing date is March 11.</li><li>Yesterday's close was $1.48.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440768\" data-linked=\"Aptevo down 45% on pricing of equity offering\" data-tweet=\"$APVO - Aptevo down 45% on pricing of equity offering https://seekingalpha.com/news/3440768-aptevo-down-45-on-pricing-of-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3440768-aptevo-down-45-on-pricing-of-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440765\" data-ts=\"1551970845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARQL\" target=\"_blank\">ARQL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440765-arqule-up-49-after-q4-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArQule up 49% after Q4 report</a></h4><ul><li>ArQule (<a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a> <font color=\"green\">+48.6%</font>) is up on more than double normal volume in early trade following its <a href=\"https://seekingalpha.com/pr/17436534-arqule-reports-fourth-quarter-full-year-2018-financial-results\" target=\"_blank\">Q4 repor</a>t that featured a revenue beat, albeit by only $1.1M, from its licensing deal with Sinovant.</li><li><strong>2019 guidance</strong>: Revenue: $3M - 5M; loss/share: ($0.39 - 0.37); quick asset balance at year-end: $60M - 63M.</li><li>Key milestones:</li><li>ARQ 531: complete dose escalation portion of Phase 1 study in B-cell blood cancers; determine recommended dose for Phase 2. Phase 1 results to be presented at major medical conference(s).</li><li>Miransertib: initiate registration trials in Proteus syndrome and PROS.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440634-arqule-misses-0_01-beats-revenue\" target=\"_blank\">ArQule misses by $0.01, beats on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440765\" data-linked=\"ArQule up 49% after Q4 report\" data-tweet=\"$ARQL - ArQule up 49% after Q4 report https://seekingalpha.com/news/3440765-arqule-up-49-after-q4-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3440765-arqule-up-49-after-q4-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440763\" data-ts=\"1551970723\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YEXT\" target=\"_blank\">YEXT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440763-yext-hiring-over-200-in-germany\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yext hiring over 200 in Germany</a></h4><ul><li>Yext (NYSE:<a href='https://seekingalpha.com/symbol/YEXT' title='Yext, Inc.'>YEXT</a>) <a href=\"https://seekingalpha.com/pr/17436961-yext-announces-plans-hire-200-employees-germany-five-years\" target=\"_blank\">plans to hire</a> over 200 employees in Germany over five years.</li><li>The company is continuing to invest in its Berlin office, which serves as its Central Europe headquarters.</li><li>YEXT is <font color=\"green\">up 6.4%</font> after yesterday's <a href=\"https://seekingalpha.com/news/3440501-yext-plus-1_6-percent-q4-beats\" target=\"_blank\">Q4 report</a> beat analyst estimates.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440763\" data-linked=\"Yext hiring over 200 in Germany\" data-tweet=\"$YEXT - Yext hiring over 200 in Germany https://seekingalpha.com/news/3440763-yext-hiring-over-200-in-germany?source=tweet\" data-url=\"https://seekingalpha.com/news/3440763-yext-hiring-over-200-in-germany\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440751\" data-ts=\"1551969762\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CASI\" target=\"_blank\">CASI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440751-casi-pharma-on-go-to-start-pivotal-study-of-marqibo-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CASI Pharma on go to start pivotal study of Marqibo in China</a></h4><ul><li>CASI Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a>) is up <font color=\"green\">1%</font> out of the gate this morning following its <a href=\"https://seekingalpha.com/pr/17436587-casi-pharmaceuticals-announces-china-national-medical-products-administration-nmpa-approval\" target=\"_blank\">announcement </a>that the China National Medical Products Administration &#40;NMPA&#41; has signed off on its application to conduct a registration study of MARQIBO (vinCRIStine sulfate LIPOSOME injection) in certain acute lymphoblastic leukemia &#40;ALL&#41; patients.</li><li>The company <a href=\"http://www.casipharmaceuticals.com/investor-relations/news/spectrum-pharmaceuticals-out-licenses-rights-for-greater-china-to-casi-phar\" target=\"_blank\">acquired </a>the rights to the drug (and another med branded as Zevalin) in greater China from Spectrum Pharmaceuticals in September 2014.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440751\" data-linked=\"CASI Pharma on go to start pivotal study of Marqibo in China\" data-tweet=\"$CASI - CASI Pharma on go to start pivotal study of Marqibo in China https://seekingalpha.com/news/3440751-casi-pharma-on-go-to-start-pivotal-study-of-marqibo-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3440751-casi-pharma-on-go-to-start-pivotal-study-of-marqibo-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440747\" data-ts=\"1551968856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440747-five-below-seen-retail-outperformer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Below seen as retail outperformer</a></h4><ul> <li>Five Below (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a>) is called one of the few remaining growth stories in retail by Oppenheimer.</li> <li>The firm says Five Below has \"thwarted and is likely to continue to thwart unfavorable trends\" within the sector by operating a unique and defensible small-store format. The retailer is also seen enjoying significant opportunity for \"outsized\" unit expansion in the future</li> <li>Oppenheimer starts off coverage on Five Below with an Outperform rating and price target of $140.</li> <li>Shares of Five Below are <font color=\"green\">up 1.79%</font> in premarket trading to $116.92.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440747\" data-linked=\"Five Below seen as retail outperformer\" data-tweet=\"$FIVE - Five Below seen as retail outperformer https://seekingalpha.com/news/3440747-five-below-seen-retail-outperformer?source=tweet\" data-url=\"https://seekingalpha.com/news/3440747-five-below-seen-retail-outperformer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440745\" data-ts=\"1551968771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBX\" target=\"_blank\">UBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440745-cantor-likes-unity-biotech-shares-up-15-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cantor likes Unity Biotech, shares up 15% premarket</a></h4><ul><li>Thinly traded micro cap Unity Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/UBX' title='Unity Biotechnology'>UBX</a>) is up <font color=\"green\">15% </font>premarket, albeit on only 641 shares, on the heels of new coverage by Cantor Fitzgerald.</li><li>Analyst Elemer Piros (Overweight/$21) likes the company's focus on eliminating senescent cells, precursors to disease progression, to possibly reverse the disease process. Lead candidate is Phase 1-stage UBX0101 so there is a long way to go.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440745\" data-linked=\"Cantor likes Unity Biotech, shares up 15% premarket\" data-tweet=\"$UBX - Cantor likes Unity Biotech, shares up 15% premarket https://seekingalpha.com/news/3440745-cantor-likes-unity-biotech-shares-up-15-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3440745-cantor-likes-unity-biotech-shares-up-15-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440741\" data-ts=\"1551968532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440741-kr-bldp-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KR, BLDP among premarket losers</a></h4><ul><li>Aptevo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a>) <font color=\"red\">-38%</font> on <a href=\"https://seekingalpha.com/news/3440503-aptevo-readies-equity-offering-shares-12-percent-hours\" target=\"_blank\">equity offering</a>.</li><li>Resideo Technologies (NYSE:<a href='https://seekingalpha.com/symbol/REZI' title='Resideo Technologies, Inc.'>REZI</a>) <font color=\"red\">-19%</font> on <a href=\"https://seekingalpha.com/news/3440619-resideo-technologies-misses-0_10-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>The Kroger (NYSE:<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3440668-kroger-misses-0_04-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>TDH Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a>) <font color=\"red\">-11%</font>.</li><li>Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3440705-barnes-and-noble-beats-0_14-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Ballard Power Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/BLDP' title='Ballard Power Systems, Inc.'>BLDP</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3440565-ballard-power-systems-misses-0_02-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>International Game Technology PLC (NYSE:<a href='https://seekingalpha.com/symbol/IGT' title='International Game Technology'>IGT</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3440622-international-game-technology-misses-0_09-revenue-line\" target=\"_blank\">Q4 earnings</a>.</li><li>Burlington Stores (NYSE:<a href='https://seekingalpha.com/symbol/BURL' title='Burlington Stores, Inc'>BURL</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3440623-burlington-beats-0_06-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Apellis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/APLS' title='Apellis Pharmaceuticals, Inc.'>APLS</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3440429-apellis-readies-75m-equity-offering\" target=\"_blank\">equity offering</a>.</li><li>Xunlei (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>) <font color=\"red\">-5%</font> on <a href=\"https://seekingalpha.com/news/3440601-xunlei-reports-q4-results\" target=\"_blank\">Q4 earnings</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440741\" data-linked=\"KR, BLDP among premarket losers\" data-tweet=\"$APVO $REZI $KR - KR, BLDP among premarket losers https://seekingalpha.com/news/3440741-kr-bldp-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440741-kr-bldp-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440734\" data-ts=\"1551968201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOV\" target=\"_blank\">HOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440734-hovnanian-misses-0_02-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hovnanian misses by $0.02, misses on revenue</a></h4><ul><li>Hovnanian (NYSE:<a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a>): Q1 GAAP EPS of -$0.12 <span style=\"color:red\">misses by $0.02</span>.</li><li>Revenue of $380.6M (-8.8% Y/Y) <font color=\"red\">misses by $4.4M</font>.</li><li>Shares <font color=\"green\">+3.2%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17437115-hovnanian-enterprises-reports-fiscal-2019-first-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440734\" data-linked=\"Hovnanian misses by $0.02, misses on revenue\" data-tweet=\"$HOV - Hovnanian misses by $0.02, misses on revenue https://seekingalpha.com/news/3440734-hovnanian-misses-0_02-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3440734-hovnanian-misses-0_02-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440733\" data-ts=\"1551968084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440733-clmt-renn-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CLMT, RENN among premarket gainers</a></h4><ul><li>Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics Inc'>SEEL</a>) <font color=\"green\">+55%</font> on <a href=\"https://seekingalpha.com/pr/17436695-seelos-therapeutics-announces-acquisition-exclusive-license-intellectual-property-uc-regents\" target=\"_blank\">acquisition</a> an exclusive license to intellectual property owned by The Regents of the University of California.</li><li>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+33%.</font></li><li>Altimmune (NASDAQ:<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a>) <font color=\"green\">+28%</font> on robust volume on <a href=\"https://seekingalpha.com/news/3440680-altimmune-44-percent-premarket\" target=\"_blank\">no apparent news</a>.</li><li>Reebonz Holding (<a href='https://seekingalpha.com/symbol/RBZ' title='Reebonz Holding Ltd. Class A'>RBZ</a>) <font color=\"green\">+28%</font> on strategic <a href=\"https://seekingalpha.com/pr/17436181-reebonz-announces-strategic-partnership-komehyo\" target=\"_blank\">partnership</a> with Komehyo.</li><li>Calumet Specialty Products Partners, L.P. (NASDAQ:<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a>) <font color=\"green\">+21%</font> on <a href=\"https://seekingalpha.com/news/3440636-calumet-specialty-beats-0_41-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Co-Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/CODX' title='Co-Diagnostics'>CODX</a>) <font color=\"green\">+13% </font>on <a href=\"https://seekingalpha.com/pr/17436492-co-diagnostics-inc-receives-ce-mark-zika-dengue-chikungunya-multiplex-test\" target=\"_blank\">obtaining</a> CE mark regulatory clearance to be sold as an in vitro diagnostic for the diagnosis of Zika, dengue, and chikungunya in accepting markets.</li><li>Guidewire Software (NYSE:<a href='https://seekingalpha.com/symbol/GWRE' title='Guidewire Software, Inc.'>GWRE</a>) <font color=\"green\">+13%</font> on <a href=\"https://seekingalpha.com/news/3440489-guidewire-plus-8_7-percent-q2-beats-upside-outlook\" target=\"_blank\">Q2 earnings</a>.</li><li>Health Insurance Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a>) <font color=\"green\">+13%</font> on <a href=\"https://seekingalpha.com/news/3440453-health-insurance-innovations-beats-0_21-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>GrafTech (NYSE:<a href='https://seekingalpha.com/symbol/EAF' title='GrafTech International'>EAF</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/pr/17436316-graftech-announces-withdrawal-proposed-secondary-offering\" target=\"_blank\">withdrawal</a> of proposed secondary offering.</li><li>Renren (NYSE:<a href='https://seekingalpha.com/symbol/RENN' title='Renren Inc.'>RENN</a>) <font color=\"green\">+7%</font>.</li><li>Sequential Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a>) <font color=\"green\">+6%</font> on new <a href=\"https://seekingalpha.com/pr/17436909-sequential-brands-group-announces-new-collaboration-heelys-harlem-globetrotters\" target=\"_blank\">collaboration</a> between Heelys and the Harlem Globetrotters.</li><li>OHR Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/OHRP' title='Ohr Pharmaceutical, Inc.'>OHRP</a>) <font color=\"green\">+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440733\" data-linked=\"CLMT, RENN among premarket gainers\" data-tweet=\"$SEEL $BPTH $ALT - CLMT, RENN among premarket gainers https://seekingalpha.com/news/3440733-clmt-renn-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3440733-clmt-renn-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440726\" data-ts=\"1551967318\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCI\" target=\"_blank\">JCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440726-johnson-controlsplus-3-buybacks-on-tap\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Johnson Controls +3% with buybacks on tap</a></h4><ul> <li>Johnson Controls International (NYSE:<a href='https://seekingalpha.com/symbol/JCI' title='Johnson Controls International plc'>JCI</a>) says it has an additional $8.5B in share repurchases ready to go.</li><li>The new buyback authorization is subject to the completion of the previously announced sale of the company's power solutions business. Johnson Controls has received U.S. and European antitrust approvals relating to the sale and is targeting to close the transaction no later than June 30.</li> <li>\"When completed, the sale of our power solutions business will streamline our portfolio and increase long-term shareholder value by creating a pure-play buildings technology and solutions provider focused on execution and increasing financial flexibility,\" says Johnson Controls CEO George Oliver.</li>  <li>JCI  <font color=\"green\">+2.65%</font> premarket to  $36.09.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17436881-johnson-controls-announces-additional-8_5-billion-share-repurchase-authorization\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440726\" data-linked=\"Johnson Controls +3% with buybacks on tap\" data-tweet=\"$JCI - Johnson Controls +3% with buybacks on tap https://seekingalpha.com/news/3440726-johnson-controlsplus-3-buybacks-on-tap?source=tweet\" data-url=\"https://seekingalpha.com/news/3440726-johnson-controlsplus-3-buybacks-on-tap\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440722\" data-ts=\"1551967077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BUD\" target=\"_blank\">BUD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440722-rbc-capital-warns-on-anheuser-busch-inbev\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC Capital warns on Anheuser-Busch InBev</a></h4><ul> <li>RBC Capital removes Anheuser-Busch InBev (NYSE:<a href='https://seekingalpha.com/symbol/BUD' title='Anheuser-Busch InBev SA/NV'>BUD</a>) from its European Best Ideas list and downgrades the beer stock to Sector Perform.</li> <li>The firm doesn't see a path forward for Anheuser-Busch to improve profit margins, \"We also refer to the rapidity of its rehabilitation from being an over-leveraged pariah,\" warns RBC.</li> <li>Shares of BUD are <font color=\"red\">down 1.00%</font> in premarket trading to $81.31.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440722\" data-linked=\"RBC Capital warns on Anheuser-Busch InBev\" data-tweet=\"$BUD - RBC Capital warns on Anheuser-Busch InBev https://seekingalpha.com/news/3440722-rbc-capital-warns-on-anheuser-busch-inbev?source=tweet\" data-url=\"https://seekingalpha.com/news/3440722-rbc-capital-warns-on-anheuser-busch-inbev\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440713\" data-ts=\"1551966384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440713-barnes-nobleminus-11-after-ebitda-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble -11% after EBITDA disappoints</a></h4><ul> <li>Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) falls sharply after the retailer turns in another disappointing earnings report.</li> <li>Comparable sales were up 1.1% during <a href=\"https://seekingalpha.com/pr/17436859-barnes-and-noble-reports-fiscal-2019-third-quarter-results\" target=\"_blank\">FQ3</a>. Adjusted EBITDA fell to $133M from $140M a year ago after higher marketing and promotional spending chipped away. Looking ahead, Barnes &amp; Noble sees 2019 EBITDA of $140M to $155M vs. $165M consensus.</li> <li>B&amp;N Chairman Len Riggio puts a positive spin on the quarter, saying, \"sales benefitted from our new ad campaign, increased marketing and promotions, and an improved omni-channel experience for our customers.\" Those efforts are expected to lay the foundation for sustained growth.</li> <li>Shares of Barnes and Noble are <font color=\"red\">down 11.11% </font>premarket to $5.20 (6-month low).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440705-barnes-and-noble-beats-0_14-misses-revenue\" target=\"_blank\">Barnes &amp; Noble beats by $0.14, misses on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440713\" data-linked=\"Barnes &amp; Noble -11% after EBITDA disappoints\" data-tweet=\"$BKS - Barnes &amp; Noble -11% after EBITDA disappoints https://seekingalpha.com/news/3440713-barnes-nobleminus-11-after-ebitda-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3440713-barnes-nobleminus-11-after-ebitda-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440712\" data-ts=\"1551966070\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOMX\" target=\"_blank\">FOMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440712-fda-accepts-foamix-nda-for-acne-treatment-fmx101-shares-up-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Foamix NDA for acne treatment FMX101; shares up 4% premarket</a></h4><ul><li>Foamix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/FOMX' title='Foamix Pharmaceuticals'>FOMX</a>) is up <font color=\"green\">4% </font>premarket on modest volume following the FDA's <a href=\"https://seekingalpha.com/pr/17436769-foamix-announces-fda-acceptance-new-drug-application-fmx101-minocycline-foam-treatment\" target=\"_blank\">acceptance </a>of its marketing application seeking approval for FMX101, a topical minocyline foam, for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients at least nine years old.</li><li>The agency's action date is October 20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440712\" data-linked=\"FDA accepts Foamix NDA for acne treatment FMX101; shares up 4% premarket\" data-tweet=\"$FOMX - FDA accepts Foamix NDA for acne treatment FMX101; shares up 4% premarket https://seekingalpha.com/news/3440712-fda-accepts-foamix-nda-for-acne-treatment-fmx101-shares-up-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3440712-fda-accepts-foamix-nda-for-acne-treatment-fmx101-shares-up-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440707\" data-ts=\"1551965631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFM\" target=\"_blank\">SFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440707-sprouts-farmers-market-follows-kroger-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprouts Farmers Market follows Kroger lower</a></h4><ul> <li>Sprouts Farmers Market (NASDAQ:<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a>) is <font color=\"red\">down 2.44%</font> in premarket trading in a move that looks to be tied to Kroger's painful earnings report.</li> <li>Kroger's technology spending on its pickup and delivery programs continue to be a negative drag on profit. Sprouts is also spending more on tech initiatives after ending its partnership with Amazon Prime.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3440684-kroger-minus-9-percent-margins-tighten\" target=\"_blank\">Kroger -9% after margins tighten</a> (March 7)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3440707\" data-linked=\"Sprouts Farmers Market follows Kroger lower\" data-tweet=\"$SFM - Sprouts Farmers Market follows Kroger lower https://seekingalpha.com/news/3440707-sprouts-farmers-market-follows-kroger-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3440707-sprouts-farmers-market-follows-kroger-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440702\" data-ts=\"1551965453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTX\" target=\"_blank\">APTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440702-aptinyx-down-9-premarket-on-allergan-rapastinel-flop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptinyx down 9% premarket on Allergan rapastinel flop</a></h4><ul><li>Thinly traded micro cap Aptinyx (NASDAQ:<a href='https://seekingalpha.com/symbol/APTX' title='Aptinyx'>APTX</a>) is down <font color=\"red\">9%</font> premarket, albeit on only 195 shares, in sympathy with the selloff in Allergan after it <a href=\"https://seekingalpha.com/news/3440496-allergans-rapastinel-flunks-late-stage-mdd-studies-shares-5-percent-hours\" target=\"_blank\">announced </a>a failed late-stage study of rapastinel in major depressive disorder &#40;MDD&#41;.</li><li>The company co-discovered rapastinel, designated as AGN-241751, with collaboration partner Allergan who <a href=\"https://www.prnewswire.com/news-releases/allergan-exercises-option-to-acquire-compound-from-aptinyx-discovery-platform-under-ongoing-research-collaboration-300652397.html\" target=\"_blank\">exercised </a>its option to acquire the NMDA receptor modulator in May 2018.</li><li>It has three other NMDA receptor modulators in either Phase 1 or 2 <a href=\"https://www.aptinyx.com/pipeline/\" target=\"_blank\">development</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3440702\" data-linked=\"Aptinyx down 9% premarket on Allergan rapastinel flop\" data-tweet=\"$APTX - Aptinyx down 9% premarket on Allergan rapastinel flop https://seekingalpha.com/news/3440702-aptinyx-down-9-premarket-on-allergan-rapastinel-flop?source=tweet\" data-url=\"https://seekingalpha.com/news/3440702-aptinyx-down-9-premarket-on-allergan-rapastinel-flop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440698\" data-ts=\"1551965213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRIB\" target=\"_blank\">TRIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440698-trinity-biotech-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trinity Biotech beats by $0.03, beats on revenue</a></h4><ul><li>Trinity Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/TRIB' title='Trinity Biotech PLC'>TRIB</a>): Q4 GAAP EPS of $0.07 <span style=\"color:green\">beats by $0.03</span>.</li><li>Revenue of $24.5M (-0.4% Y/Y) <font color=\"green\">beats by $1M</font>.</li><li>Shares <font color=\"green\">+8.7%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17436839-trinity-biotech-announces-quarter-4-fiscal-year-2018-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3440698\" data-linked=\"Trinity Biotech beats by $0.03, beats on revenue\" data-tweet=\"$TRIB - Trinity Biotech beats by $0.03, beats on revenue https://seekingalpha.com/news/3440698-trinity-biotech-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3440698-trinity-biotech-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3440697\" data-ts=\"1551965204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAYO\" target=\"_blank\">ZAYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3440697-zayoplus-2_4-on-starboard-request-for-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zayo +2.4% on Starboard request for sale</a></h4><ul><li>Starboard Value <a href=\"https://www.cnbc.com/2019/03/07/starboard-builds-stake-in-zayo-presses-for-sale.html\" target=\"_blank\">sends a letter</a> to Zayo (NYSE:<a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group'>ZAYO</a>) asking the company to consider a sale. Starboard has a 4% stake in the communications infrastructure provider.</li><li>The activist investor thinks a sale might be the best option for shareholders if the process is conducted in a \"purely objective way\" that excludes potential conflicts of interest like possible roles for management and board members.</li><li>Zayo's debt totaled $5.9B at the end of December.</li><li>Yesterday, the company <a href=\"https://seekingalpha.com/news/3440253-zayo-plus-10-percent-postponed-meeting-strategic-options\" target=\"_blank\">postponed</a> its annual meeting to consider its strategic options.</li><li>ZAYO shares are <font color=\"green\">up 2.4%</font> pre-market to $27.99.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440398-group-including-colony-capital-jv-weighs-bid-zayo-bloomberg\" target=\"_blank\">Group including Colony Capital JV weighs bid for Zayo: Bloomberg</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3440697\" data-linked=\"Zayo +2.4% on Starboard request for sale\" data-tweet=\"$ZAYO - Zayo +2.4% on Starboard request for sale https://seekingalpha.com/news/3440697-zayoplus-2_4-on-starboard-request-for-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3440697-zayoplus-2_4-on-starboard-request-for-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}